Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
 
A Phase III, Double -blind, Randomized, Crossover Study of Plerixafor V ersus G -CSF in 
the Treatment of Patients with WHIM Syndrome  
 
 
 
Protocol Number:    14-I-0185  
Version Description:                       Version 6.0 
Version Date:                                 January 9 , 201 9 
Abbreviated Title:                          Plerixafor  vs. G-CSF in WHIMS 
Location of the Study:   NIH Clinical Center  
Total Subjects to be accrue d:         30 
Proposed Period :                            6 years 
  
IND:     118767  
Name [CONTACT_43632]:    plerixafor  and G -CSF  
Holder:     OCRPRO , DCR, NIAID  
    
 
 
USponsored by  
[CONTACT_916] (OCRPRO) 
Division of Clinical Research (DCR), Office of the Director  
National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health ( NIH)  
 
 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 2 of 74 
 
 STUDY STAFF ROSTER  
 
Principal Investigator:   [INVESTIGATOR_10086] H. McDermott, MD 
Laboratory of Molecular Immunology ( LMI)/NIAID 
 Phone: 301-496 -8483  
E-mail: [EMAIL_1654]   
 
Associate Investigators:   Philip M. Murphy, MD      
LMI/NIAID    
Phone: 301-[ADDRESS_90566] Defenses (LHD)/NIAID  
     Phone: 301-[ADDRESS_90567] Defenses (LHD)/NIAID  
     Phone: 301-[ADDRESS_90568]/Study  
Coordinator(s):    Daniel Velez, RN    
LMI/NIAID    
Phone: 301-594 -1549  
      Elena Cho, RN  
     LMI/NIAID 
     Phone: 301-761 -7280  
 
Statistician:     Dean Follmann, PhD 
     Biostatistics Research Branch/ DCR/NIAID  
     Phone: 301-451 -5128  
 
NIH Pharmacy  (NIH) :   Michael Kolf  
     NIH Pharmacy /NIH/Clinical Center  
     Phone: 301-496 -1031  
 Sponsor Medical Monitor :  Marc Teitelbaum , MD  
Leidos Biomedical Research, Inc.  
[ADDRESS_90569]  
Frederick, MD [ZIP_CODE]  
Tel: 301 -228-4707   
Email: 
[EMAIL_1655] 40T 
 
Institutional Review Board:  NIAID IRB  
  
   
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 3 of 74 
 
  Consultants:     
    Melissa Meridith, MD 
    Gynecology, NHGRI  
    301-[ADDRESS_90570] Cowen, MD  
     Dermatology , NCI 
  301-496 -4299  
   John DiGiovanna , MD   
  Dermatology, NCI  
  301-402 -1607  
 
Jeffrey H. Kim, MD  
     ENT, NIDCD 
  301-496 -4299  
 
    Carmen Brewer, PhD  
     Audiology, NIDCD 
  301-496 -5294  
 
    Katherine Calvo, MD  
     Hematologic Pathology , DLM/CC  
  301-594 -9578  
 
Pamela Gardner, DDS  
     Dentistry, NIDCR  
  301-443 -8010  
      
     Thomas Fleisher, MD  
     Clinical Immunology, DLM /CC 
     301-496 -5568  
      Alison McBride, PhD 
     Virology, LVD /NIAID  
     301-496 -1370  
      Chris Buck, PhD 
     Virology, LCO /NCI 
     301-594 -7060  
 
  
Plerixafor  vs. G -CSF in WHIMS – Version 6.[ADDRESS_90571] OF ABBREVIATIONS 40T ...................................................................................................... 13  
40TPROTOCOL SUMMARY 40T ........................................................................................................... 15  
40TPRÉCIS 40T ........................................................................................................................................ 17  
40TSTUDY SCHEMA 40T ...................................................................................................................... 18  
40T1 40T 40TBACKGROUND INF ORMATION AND SCIENTI FIC RATIONALE 40T .................... 19  
40T1.1 40T 40TBackground Information 40T .............................................................................................. 19  
40T1.1.1 40T 40TCXCR4 40T ................................................................................................................................. 19 
40T1.1.2 40T 40TWHIMS 40T ................................................................................................................................ 19 
40T1.2 40T 40TDescription of Study Agent: Mozobil™ (plerixafor) 40T ................................................... 20  
40T1.2.1 40T 40TSummary of Previous Pre -Clinical Studies 40T .......................................................................... 21 
40T1.2.2 40T 40TSummary of Relevant Clinical Studies 40T ................................................................................ 22 
40T1.3 40T 40TDescription of Comparator Treatment: G -CSF 40T ............................................................ 22  
40T1.3.1 40T 40TSummary of Relevant Clinical Studies 40T ................................................................................ 22 
40T1.4 40T 40TScientific Rationale and Clinical Justification 40T ............................................................. 23  
40T1.5 40T 40TPreliminary Report of Unexpected Adverse Events in this Study 40T ............................... 24  
40T1.5.1 40T 40TAn Incident of a New Psoriasis-like Rash 40T ........................................................................... 24 
40T1.5.2 40T 40TJoint Pain (Arthralgia) and an Incident of Reactive Arthritis 40T .............................................. 24 
40T2 40T 40TSTUDY OBJECTIVES 40T ................................................................................................ 26  
40T2.1 40T 40TPrimary Objective 40T ........................................................................................................ 26  
40T2.2 40T 40TSecondary Objectives 40T ................................................................................................... 26  
40T2.3 40T 40TExploratory Objectives 40T ................................................................................................. 26  
40T3 40T 40TSTUDY DESIGN 40T ......................................................................................................... 26  
40T3.1 40T 40TDescription of the Study Design 40T .................................................................................. 26  
40T3.2 40T 40TStudy Endpoints 40T ........................................................................................................... 27  
40T3.2.1 40T 40TPrimary Endpoint 40T ................................................................................................................. 27 
Plerixafor  vs. G -CSF in WHIMS – Version 6.[ADDRESS_90572] Feeding Women 40T ............................. 28  
40T4.5 40T 40TJustification for Exclusion of Children <10 Years of Age 40T ........................................... 28  
40T5 40T 40TSTUDY AGENT AND INTERVENTIONS 40T ............................................................... 28  
40T5.1 40T 40TDrug Acquisition 40T .......................................................................................................... 28  
40T5.1.1 40T 40TPlerixafor: Provided by [CONTACT_83138] 40T ................................................................................. 28 
40T5.1.2 40T 40TG-CSF: Obtained Commercially 40T .......................................................................................... 29 
40T5.2 40T 40TDisposition and Dispensation 40T ....................................................................................... 29  
40T5.2.1 40T 40TFormulation, Packaging, and Labeling 40T ................................................................................ 29 
40T5.2.1.1 40T 40TPlerixafor Packaging from Manufacturer 40T .................................................................... 29 
40T5.2.1.2 40T 40TPlerixafor Repackaging for Study and/or Shipment to Study Participants 40T ................. 29 
40T5.2.1.3 40T 40TG-CSF Packaging from Manufacturer 40T ........................................................................ 29 
40T5.2.1.4 40T 40TG-CSF Repackaging for Study and/or Shipment to Study Participants 40T ...................... 29 
40T5.2.2 40T 40TLabeling of Study Drug 40T ....................................................................................................... 29 
40T5.3 40T 40TStudy Agent Storage and Stability 40T ............................................................................... 29  
40T5.3.1 40T 40TStorage at NIH-CC 40T ............................................................................................................... 30 
40T5.3.2 40T 40TShipment to Participants' Home 40T ........................................................................................... [ADDRESS_90573] Memory Aid: Injection Site, Injection Volume, Adverse Reactions 40T ...................... [ADDRESS_90574] Accountability Procedures 40T ................................................................... 30  
40T5.6.1 40T 40TPlerixafor 40T.............................................................................................................................. 30 
40T5.6.2 40T 40TG-CSF 40T .................................................................................................................................. 30 
40T6 40T 40TSTUDY SCHEDULE AND A CTIVITIES 40T .................................................................. 30  
40T6.1 40T 40TRecruitment 40T .................................................................................................................. 30  
40T6.2 40T 40TScreening 40T ...................................................................................................................... 31  
40T6.2.1 40T 40TLabs and Procedures 40T ............................................................................................................ 31 
40T6.2.2 40T 40TAssessment of Overall Health 40T .............................................................................................. 31 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 6 of 74 
 
 40T6.3 40T 40TInitial Evaluation and Baseline Assessment Period 40T ..................................................... 31  
40T6.3.1 40T 40TMeasurement of Immunological Markers 40T ............................................................................ 31 
40T6.3.2 40T 40TEvaluations: Dermatology, GYN, Dentistry, ENT, Audiology, and Clinical Photography 40T . 31 
40T6.3.3 40T 40TAdditional Evaluations if Clinically Indicated (e.g. PFT and CT of Chest and Sinus) 40T ........ 31 
40T6.3.4 40T 40TBaseline Measure of Bone Density and Spleen Size 40T ........................................................... 32 
40T6.3.5 40T 40TResearch Blood 40T .................................................................................................................... 32 
40T6.3.6 40T 40TWart and/or Skin Biopsy (optional) 40T ..................................................................................... 32 
40T6.3.7 40T 40TBone Marrow Biopsy (optional) 40T .......................................................................................... [ADDRESS_90575]’s Home Locale 40T .............. [ADDRESS_90576] Study/Comparator Dose (at least [ADDRESS_90577]
P dose) 40T
 33 
40T6.4.2 40T 40TAssessment of Overall Health (within [ADDRESS_90578]
P dose) 40T ..................................... 33 
40T6.4.3 40T 40TConfirm Study Drug Shipment/Injection, Memory Aid, Local Labs, and Reporting 
Infections 40T ........................................................................................................................................... [ADDRESS_90579]
P Study/Comparator Dose 40T .......................................... [ADDRESS_90580] Study/Comparator Dose (Day 0) 40T ............................................................... 34 
40T6.4.5.1 40T 40TPrior to Injection 40T.......................................................................................................... 34 
40T6.4.5.2 40T 40TAfter Study Drug Injection 40T .......................................................................................... 34 
40T6.4.5.3 40T 40TProcedures Prior to Leaving NIH-CC 40T ......................................................................... 34 
40T6.5 40T 40TEquilibration Period for the Treatment (8 weeks) 40T ........................................................ [ADDRESS_90581]’s Local Medical Facility Every 2 Weeks 40T ...................................... 34 
40T6.5.2 40T 40TDose May be Adjusted to Maintain ANC Between 500 -1500 cells/μL 40T ............................... 34 
40T6.6 40T 40TTreatment Period (52 weeks) 40T ....................................................................................... 34  
40T6.6.1 40T 40TAssessments at NIH-CC Every 4 Months 40T ............................................................................ 35 
40T6.6.1.1 40T 40TLabs 40T ............................................................................................................................. 35 
40T6.6.1.2 40T 40TAssessment of Overall Health and Safety 40T ................................................................... 35 
40T6.6.1.3 40T 40TMeasurement of Immunological Markers 40T ................................................................... 35 
40T6.6.1.4 40T 40TEvaluations and Consults for Assessment of Infections 40T .............................................. 35 
40T6.6.1.5 40T 40TResearch Blood 40T ........................................................................................................... 35 
40T6.6.1.6 40T 40TQuality of Life Assessment 40T ......................................................................................... 35 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 7 of 74 
 
 40T6.6.1.7 40T 40TSkin and Wart Biopsies (optional) 40T .............................................................................. 35 
40T6.6.2 40T 40TCBC w/diff, ESR, and Chemistries Every [ADDRESS_90582]’s Local Medic al Facility 40T .. [ADDRESS_90583]’s Local Provider for New or Worsening Infections 40T ............................... 35 
40T6.6.4 40T 40TEnd of Treatment (EOT) Visit for a Study Drug 40T ................................................................. [ADDRESS_90584]’s Pre -study Treatment 40T ............................................................. 36  
40T6.7.1 40T 40TWashout Period (2 Days) 40T ..................................................................................................... 36 
40T6.7.2 40T 40TMonitoring the G -CSF Dose (1 -2 Months) 40T .......................................................................... 36 
40T6.7.3 40T 40TStudy Completion Visit 40T ........................................................................................................ 36 
40T6.8 40T 40TEarly Completion of Treatment Due to Unwillingness or Inability to Receive Study 
Agent 40T ............................................................................................................................. 36  
40T7 40T 40TSTUDY PROCEDURES AND EVALUATIONS 40T ....................................................... 36  
40T7.1 40T 40TAbsolute Neutrophil Count (ANC) 40T .............................................................................. 36  
40T7.1.1 40T 40TTime of Day Measurement for ANC: Prior to Study Dose 40T .................................................. 37 
40T7.1.2 40T 40TTarget ANC during 8 week Equilibration Period (500 – 1500 cells/µL) 40T ............................. 37 
40T7.1.2.1 40T 40TSubjects with a Baseline ANC > 500 cells/µL 40T ............................................................ 37 
40T7.1.2.2 40T 40TSubjects Unable to Attain ANC >500 cells/μL During Equilibration, Despi[INVESTIGATOR_83077] 40T 37 
40T7.1.3 40T 40TTarget ANC during the 52 week Treatment Period (500 – 7500 cells/µL) 40T.......................... 37 
40T7.1.4 40T 40TDose Range for Low-Dose Treatment 40T ................................................................................. 37 
40T7.2 40T 40TAdjusting the Study Dose to Meet ANC Goals 40T ........................................................... 38  
40T7.2.1 40T 40TInitial Study/Comparator Drug Doses during Equilibration Period 40T ..................................... 38 
40T7.2.2 40T 40TAdjustment for ANC <500 cells/µL 40T .................................................................................... 38 
40T7.2.3 40T 40TAdjustment for ANC between 500 – 1500 cells/µL in the Equilibration Period 40T ................. 38 
40T7.2.4 40T 40TAdjustment for ANC > 1500 cells/µL in the Equilibration Period 40T ...................................... 38 
40T7.2.5 40T 40TAdjustment for ANC > 7500 cells/µL in the Treatment Period 40T ........................................... 38 
40T7.3 40T 40TImmune Status: Leukocyte Immunophenotypes 40T .......................................................... 38  
40T7.4 40T 40TMedication Compliance: Study Drug and Prophylactic Antibiotics 40T ............................ [ADDRESS_90585] Memory Aid 40T ............................................................................................................ 39 
40T7.5.1.1 40T 40TInjection Site Reaction 40T ................................................................................................ 39 
40T7.5.1.2 40T 40TBone (Skeletal) Pain: back, arms and legs 40T .................................................................. 39 
40T7.5.1.3 40T 40TOther Pain: shoulder, abdominal etc. 40T .......................................................................... 39 
Plerixafor  vs. G -CSF in WHIMS – Version 6.[ADDRESS_90586] Specifies Other Symptoms or Adverse Events. 40T .............................................. 40 
40T7.5.2 40T 40TCBC, Chemistries, ESR, and Pregnancy for Women of Childbearing Potential 40T ................. 40 
40T7.5.3 40T 40TSplenic Enlargement 40T ............................................................................................................ 41 
40T7.5.3.1 40T 40TSpleen Ultrasonography 40T .............................................................................................. 41 
40T7.5.3.2 40T 40TSpleen Assessment as part of Physical Examination at Research Assessment 40T ........... 41 
40T7.5.4 40T 40TElectrocardiogram 40T ................................................................................................................ 41 
40T7.5.5 40T 40TEchocardiogram 40T ................................................................................................................... 41 
40T7.5.6 40T 40TDual -energy X-ray Absorptiometry (DEXA) Scans 40T ............................................................ [ADDRESS_90587] Memory Aid: Symptoms of Infections 40T ................................................................... 41 
40T7.6.1.1 40T 40TIncidence and Severity of Fever 40T .................................................................................. 41 
40T7.6.1.2 40T 40TNumber of Days with Fever 40T ........................................................................................ 41 
40T7.6.1.3 40T 40TChange in Severity of Chronic Infection 40T ..................................................................... 41 
40T7.6.1.4 40T 40TVisits to Local Provider for Medical Exam or Treatment 40T ........................................... 41 
40T7.6.1.5 40T 40TIncidence and Duration of Antibiotic  for Treatment 40T ................................................... 41 
40T7.6.2 40T 40TClinical Diagnosis and Treatment of Infections 40T................................................................... 42 
40T7.6.2.1 40T 40TLocal Provider Completes a Diagnosis and Treatment Form (option 1) 40T ..................... [ADDRESS_90588] or Provider forwards Documents Relating to the Infection (option 2) 40T ........... 42 
40T7.6.3 40T 40TENT and Audiology Evaluation at NIH -CC 40T ........................................................................ 42 
40T7.6.4 40T 40TDental and Oral Evaluation 40T .................................................................................................. 42 
40T7.6.5 40T 40TPFT for Subjects with Chronic Respi[INVESTIGATOR_83078] 40T ........................................................ 42 
40T7.7 40T 40TMonitoring Warts 40T ......................................................................................................... 42  
40T7.7.1 40T 40TPhotos of Infections and Warts 40T ............................................................................................ 42 
40T7.7.2 40T 40TRecording the Quantity and Severity of Warts 40T .................................................................... 42 
40T7.7.3 40T 40TDermatology Evaluation 40T ...................................................................................................... 43 
40T7.7.4 40T 40TGU/GYN Evaluation 40T ............................................................................................................ 43 
40T7.8 40T 40TSpecimen Preparation, Handling, and Shippi[INVESTIGATOR_007] 40T .......................................................... 43  
40T7.9 40T 40TQuality of Life (SF36 v2) 40T ............................................................................................. [ADDRESS_90589] for Excess Tissue 40T ............................................................................................ 43  
40T8 40T 40TPOTENTIAL RISKS AND BENEFITS 40T ...................................................................... 43  
Plerixafor  vs. G -CSF in WHIMS – Version 6.[ADDRESS_90590] by [CONTACT_83139] 40T ............................................................................................... 48 
40T9.5.2 40T 40TAt Completion of Study 40T ....................................................................................................... 48 
40T10 40T 40TREMUNERATION PLAN FOR SUBJECTS 40T ............................................................. 48  
40T11 40T 40TASSESSMENT OF SAFETY 40T ...................................................................................... 48  
40T11.1 40T 40TDocumenting, Recording, and Reporting Adverse Events 40T .......................................... 48  
40T11.2 40T 40TDefinitions 40T .................................................................................................................... 48  
40T11.3 40T 40TInvestigator Assessment of Adverse Events 40T ................................................................ 50  
40T11.3.1 40T 40TSeverity 40T ............................................................................................................................ 50 
40T11.3.2 40T 40TCausality 40T .......................................................................................................................... 50 
40T11.4 40T 40TInvestigator Reporting Responsibilities to the Sponsor 40T ............................................... 51  
40T11.4.1 40T 40TAdverse Events 40T ................................................................................................................ 51 
40T11.4.2 40T 40TSerious Adverse Events 40T ................................................................................................... 51 
40T11.4.3 40T 40TUnanticipated Problems 40T ................................................................................................... 52 
40T11.4.4 40T 40TProtocol -Specified Events 40T ............................................................................................... 52 
40T11.4.5 40T 40TPregnancy 40T ........................................................................................................................ 52 
40T11.5 40T 40TInvestigator Reporting Responsibilities to the NIAID IRB 40T ......................................... 52  
40T11.5.1 40T 40TExpedited Reporting 40T ........................................................................................................ 52 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 10 of 74 
 
 40T11.5.2 40T 40TWaiver of Reporting Anticipated Protocol Deviations, Expected UPnonAEs and Deaths 40T
 52 
40T11.5.3 40T 40TAnnual Reports 40T ................................................................................................................ 52 
40T11.6 40T 40TFollow-up of Adverse Events and Serious Adverse Events 40T ......................................... 53  
40T11.7 40T 40TInvestigator Initiated Trial (IIT) Sponsor Obligations and Reporting Responsibilities 40T [ADDRESS_90591] 40T .............................................................................. 55  
40T12.4 40T 40TProcedures for Emergency Unblinding 40T ........................................................................ 55  
40T13 40T 40TCLINICAL MONITORING STRUCTURE 40T ................................................................ 56  
40T13.1 40T 40TSite Monitoring Plan 40T .................................................................................................... 56  
40T14 40T 40TSTATISTICAL CONSIDER ATIONS 40T ......................................................................... 56  
40T14.1 40T 40TStudy Hypotheses 40T ......................................................................................................... 56  
40T14.2 40T 40TSample Size Justification 40T ............................................................................................. 56  
40T14.3 40T 40TStudy Population 40T .......................................................................................................... 57  
40T14.4 40T 40TDescription of Analysis 40T ................................................................................................ 57  
40T14.4.1 40T 40TEfficacy Analysis – Infection Severity Score (ISS) 40T ......................................................... 57 
40T14.4.1.1 40T 40TInfection -related Events 40T .............................................................................................. 57 
40T14.4.1.2 40T 40TSeverity of Fever for an Infection -related Event 40T ......................................................... 58 
40T14.4.1.3 40T 40TLevel of Antibiotic Treatment for an Infection-related Event 40T ..................................... 58 
40T14.4.1.4 40T 40TExtent of Hospi[INVESTIGATOR_83079]-related Event 40T ............................................ 58 
40T14.4.2 40T 40TMethod of Analysis 40T ......................................................................................................... 58 
40T14.4.3 40T 40TInterim Analysis 40T .............................................................................................................. 59 
40T14.4.4 40T 40TFutility Monitoring 40T .......................................................................................................... 59 
40T14.4.5 40T 40TSafety Analysis 40T ................................................................................................................ 59 
Plerixafor  vs. G -CSF in WHIMS – Version 6.[ADDRESS_90592] Preference Assessment 40T ............................................... 61 
40T14.4.7 40T 40TRandomization 40T ................................................................................................................. 61 
40T15 40T 40TETHICS/PROTECTION OF  HUMAN SUBJECTS 40T ................................................... [ADDRESS_90593] KEEPI[INVESTIGATOR_1645] 40T ........................................................ 62  
40T16.1 40T 40TData Management Responsibilities 40T .............................................................................. 62  
40T16.2 40T 40TData Capture Methods 40T .................................................................................................. 62  
40T16.3 40T 40TTypes of Data 40T ............................................................................................................... 62  
40T16.4 40T 40TSource Documents and Access to Source Data/Documents 40T ........................................ 62  
40T16.5 40T 40TStudy Records Retention 40T .............................................................................................. 63  
40T17 40T 40TREFERENCES 40T ............................................................................................................. 64  
40TAPPENDIX A: SCHEDULE  OF PROCEDURES AND E VALUATION 40T ................................. 67  
40TAPPENDIX B: FDA APPROVED PACKAGED INSERT: PLERIXAFOR 40T ............................. 69  
40TAPPENDIX C: FDA APPROVED PACKAGE INSERT:  G-CSF 40T ............................................. 70  
40TAPPENDIX D: INFECTION SEVERITY SCORE (IS S) 40T ........................................................... 71  
40TAPPENDIX E: DOSING OF PLEXIFOR IN RENAL IMPAIRMENT 40T ..................................... 72  
40TAPPENDIX F: SAMPLE SUBJECT MEMORY AID 40T ............................................................... 73  
40TAPPENDIX G: EVALUATION OF INFECTION FORM 40T ......................................................... 74  
 
  
Plerixafor  vs. G -CSF in WHIMS – Version 6.[ADDRESS_90594] OF TABLES  
 
40TTable 1:  Sample size required to achieve 90% power under different assumptions for the mean response 
on G -CSF and plerixafor.  Power formula based on a two-sided two sample  t -test with alpha=0.[ADDRESS_90595] OF FIGURES  
 
40TFigure 1 :  Plerixafor May Reduce Infection Incidence in Patients with WHIM Syndrome. 40T ..................... 25 
 
  
Plerixafor  vs. G -CSF in WHIMS – Version 6.[ADDRESS_90596]  Adverse Drug Reaction  
AE Adverse Event/Adverse Experience  
AML  Acute Myeloid Leukemia  
ANC  Absolute Neutrophil Count  
AR Adverse Reaction  
ARDS  Acute Respi[INVESTIGATOR_39053]  
 b.i.d.   Twice per day (bis in die)  
CFR  Code of Federal Reg ulations  
CBC  Complete Blood C ount (with differential ) 
CC Clinical Center  
CrCl  Creatinine C learance (calc ulated)  
CRF  Case Report F orm 
CRIS  Clinical Research Information System (for NIH Clinical Center)  
CSO  Clinical  Safety Office  
CXCL12  CXC chemokine ligand 12, aka SDF -[ADDRESS_90597]  
ISS Infection Severity Score  
 IVIg   Intravenous I mmunoglobulin  
Plerixafor  vs. G -CSF in WHIMS – Version 6.[ADDRESS_90598] Defenses  
LMI Laboratory of Molecular Immunology  
LMF  Local Medical Facility  
MDS  Myelodysplastic Syndrome  
MED  Minim um Effective D ose 
MM Multiple M yeloma  
NCI National Cancer Institute  
NHL  non-Hodgkin ’s lymphoma  
 NIAID   National Institute of Allergy and Infectious Diseases  
NIH National Institutes of Health  
NIH-HRPP  National Institutes of Health – Human Research Protection Program  
 NIH-CC  National Institutes of Health Clinical Center  
OCRPRO  Office of Clinical Research Policy and Regulatory Operations  
OHRP  Office for Human Research Protection  
PFT Pulmonary Function Test  
PI [INVESTIGATOR_83080]-1  Stromal Cell -Derived factor -1, aka CXCL12  
SQ Subcutaneous  (Injection)  
S[LOCATION_003]R  Serious and Unexpected Suspected Adverse Reaction  
TISS  Total Infection Severity Score  
TPN  Total Parenteral Nutrition  
WBC  White Blood Cell Count  
WHIMS  Warts, Hypogammaglobulinemia, Infections, and Myelokathexis 
Syndrome  
UP Unanticipated Problem  
UPnonAE  Unanticipated Problem that is not an Adverse Event  
  
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 15 of 74 
 
 PROTOCOL SUMMARY  
 Full Title:  A Phase III , Double -blind , Randomized, Crossover Study of P lerixafor  Versus 
G-CSF in t he Treatment of Patients with WHIM Syndrome  
 
Short Title: Plerixafor vs. G-CSF in WHIMS 
 
Clinical Phase:  III 
 
IND Sponsor:  OCRPRO/DCR/ NIAID  
 
Conducted by:  [CONTACT_83140]/NIAID  
 
Principal Investigator:   [INVESTIGATOR_10086] H. McDermott , MD  
 Sample Size:   N=20  
 
Accrual Ceiling:   n = 30 
 
Study Population:   Subjects (≥10 and ≤75 years of age) with WHIMS   
 
Accrual Period:  36 months  
 
Study Design:  This is a double -blind ed, randomized, crossover study  
comparing the  efficacy of  the chemokine receptor CXCR4 antagonist  
plerixafor  to G-CSF in subjects with a clinical dia gnosis of WHIMS and 
mutations in the C -terminus of chemokine receptor CXCR4. Eligible s ubjects 
who give informed consent  are randomized to 1 year of treatment with either  
plerixafor  or G-CSF , followed by a crossover to the second  drug for 1 year . 
Each treatment arm is preceded by  a 2-day washout  period  followed by [CONTACT_1629] 8-
week  equilibration period during which study drug dosing is initiated and 
adjusted  to establish an ANC of approximately 500- 1500 cells/μL . A subject’s 
ANC is moni tored every 2 months during the  one-year treatment period s and 
study drug dosage  adjusted for ANC ≤500 cells/µL  or ≥ 7500 cells/µL . 
Participants maintain a study Memory Aid  in which they record daily 
treatments and  any new symptoms. After complet ing both treatment s, subjects 
are offered  G-CSF and enter a post -treatment observation period during which 
they continue to submit the study Memory Aid . The  study c ompletion visit 
occurs 5-[ADDRESS_90599] day of  the second year of treatment .  
 Study Duration:   6 years  
    
Study Agent/Intervention : plerixafor  (Mozobil™ ) 
Comparator:   G-CSF (Neupogen
PTM
P, filg rastim) 
 
Primary Objective:  Compare the severity of infection during treatment with each drug  
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 16 of 74 
 
      
Secondary Objectives:    
1) Compare component measures of infections.  
2) Measure the control of warts with plerixafor  versus G-CSF. 
3) Demonstrate the safety of plerixafor  and G -CSF as long -term therapy.  
4) Compare the symptoms of chronic infections.  
5) Compare quality of life (QOL).  
6) Compare drug tolerability  and assess subject  drug preference . 
7) Compare the increase of leukocyte levels from baseline.  
 
Exploratory Objective:    Measure type, location, and cause of i nfection s. 
 
Primary Endpoint: The primary endpoint is infection severity, which is measured as a composite 
of multiple weighted parameters according to rules defined in 40TAppendix D 40T. 
 
Secondary Endpoints:    
1) Component  measures of i nfection s: incidence and duration of infections, 
fever, antibiotic treatment, and  hospi[INVESTIGATOR_059] . 
2) Control of warts as defined by [CONTACT_2669] a 50% reduction in numbers, areas 
or size of existing warts, or in  new warts occurring during treatment . 
3) Blood count and immunological parameters.  
4) Clinical measures of c hronic infection . 
5) Treatment  side effects. 
6) Quality of life scores. 
7) Treatment preference. 
  
Exploratory Endpoint :  Identify causative organisms and locations of infections in WHIM S patients.   
 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 17 of 74 
 
 PRÉCIS  
 Warts, hypogammaglobul inemia, infections, and myelokathexis syndrome  (WHIMS) is a rare combined 
primary immunodeficiency disorder caused by  [CONTACT_83141]-of-function mutations in the gene for the chemokine 
receptor CXCR4 .  Normally, CXCR4 is expressed on most leukocyte  subsets and functions in part to 
promote hematopoietic stem cell (HSC) and neutrophil homing to and retention in bone marrow .
P  
PWHIM 
mutations alter the CXCR4 carboxyl terminus , which  enhances and prolongs receptor signaling. ( 40T1 40T) As a 
result, egress of normally produced and functional neutrophils from the bone marrow to the blood is 
impaired causing neutropenia, a bone marrow pathologic finding referred to as my elokathexis. A similar 
mechanism may also affect other leukocyte subsets since WHIM patients usually are panleukopenic.  
Consequently, WHIM patients are predisposed to frequent acute bacterial infections, especially in the sinopulmonary tract, that may cause chronic morbidity, respi[INVESTIGATOR_83081].  WHIM patients also have marked difficulty clearing infections with Human 
Papi[INVESTIGATOR_28597] ( HPV), resulting in persistent cutaneous and anogenital warts that in several report ed 
cases have evolved into cancer. Several deaths have also occurred due to cancer associated with Epstein - 
Barr virus (EBV) infection.  Therapi[INVESTIGATOR_83082]-specific and expensive, and 
include  Granulocyte Colony -Stimulating Factor  (G-CSF) (the drug currently approved by [CONTACT_4469] (FDA) to treat severe congenital neutropenia), intravenous immunoglobulin (IVI g), 
and prophylactic antibiotics .  None of these measures has been formally evaluated for efficacy in WHIM 
syndrome  (WHIMS); however, in our clinical experience b ased on the treatment of 24 WHIM patients  
seen at the National Institutes of Health (NIH) since 2006, recurrent bacterial infections continue to occur , 
despi[INVESTIGATOR_83083] (ANC ) can be readily maintained above 500 
cells/microliter by G-CSF and IgG levels can be restored to the normal range by [CONTACT_83142] . Thus, there 
continues to be a major unmet medical need for effective therapy in WHIMS  despi[INVESTIGATOR_83084].  Plerixafor 
(Mozobil™) i s a specific small molecule antagonist of CXCR4, licensed by [CONTACT_83143], and is th erefore a logical candidate for molecularly targeted 
treatment of WHIMS .(
40T2 40T)  The goal of treatment would be to reduce CXCR4 signaling to normal, not to 
zero, thus, absent any off-target effects, targeted chronic treatment with this agent may be safe.  In this 
regard, 2 recent short term Phase I dose- escalation studies of plerixafor, one from our group,  in a total of 
9 patients  demonstrated that the drug could safely  mobilize not only neutrophils, but also all other 
leukocy te subsets that are decreased in the blood of WHIM  patients. ( 40T3, 4 40T)  A follow -up Phase I study , 
conducted by [CONTACT_27156], in 3 patients given plerixafor 0.02- 0.04 mg/kg/d for 6 months demonstrated that 
these hematopoietic effects were durable.(5)  Moreover, the frequency of infection was reduced on 
plerixafor as compared to retrospective data mined for the three years before starting therapy and 
prospective data collected for one year after ending therapy, even though [ADDRESS_90600] ablishing the long-term 
safety and clinical efficacy (primar y endpoint: infection severity; multiple secondary endpoints including 
wart control) of plerixafor as compared to G-CSF in the treatment of WHIMS patients 10-75 years of age. 
G-CSF as a comparator  is required because of its approved use in patients with severe congenital 
neutropenia (SCN).  
 
Brief outline of study —we intend to randomize [ADDRESS_90601] comparison of 
infection severity  during treatment with both agents , at doses determined by [CONTACT_102]’s individual 
neutrophil response. A schedule of events has been provided in 
40TAppendix A 40T. Data will be analyzed as 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 18 of 74 
 
 specified in the Statistics section ( Section 14) after randomization .  Tolerability and patient drug 
preference will also be assessed.   
 
 
STUDY SCHEMA 
 
 
 
  2d 8w  52w  2d  8w  52w  
 Randomize 
to AB Arm   
Wash 
Out 
 Equilibration  Treatment A    
Wash 
Out Equilibration  Treatment B  
Screening & Initial 
Evaluation   
      
  Post Treatment 
Study Completion 
Visit ( approx. 20w)  
 Randomize 
to BA Arm   
Wash 
Out Equilibration  Treatment B    
Wash 
Out Equilibration  Treatment A  
 
 
w = week(s)  
d = day(s)  
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 19 of 74 
 
 1 BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE  
1.1 Background Information 
1.1.1 CXCR4  
CXCR4 is a member of the chemokine receptor family, which consists of 18 related 7 transmembrane -
domain, G protein-coupled chemoattractant receptors that regulate leukocyte trafficking. (6, 40T7 40T) According 
to studies in gene knockout mice, CXCR4 is essential for life and  plays a fundamental role in the 
hematopoietic, cardiovasc ular, reproductive, and nervous systems during embryonic development .( 40T8 40T) In 
the hematopoietic system, CXCR4 is important for hematopoietic stem  cell and neutrophil trafficking 
between blood and bone marrow .  In particular, reduced CXCR4 signaling promotes egres s of these cells 
from marrow whereas increased  CXCR4 signaling promotes homing to and retention of these cells in 
bone marrow. ( 40T9 40T) CXCR4 is  also an important HIV co -receptor (with CD4) used by [CONTACT_83144], but only for a minority of HIV strains, which  are found in patients mainly during the  late 
stages of disease. ( 40T10 40T) 
1.1.2 WHIMS   
Warts, h ypogammaglobul inemia, infections, and myelokathexis s yndrome (WHIMS ) is a rare congenital 
immunodeficiency disorder caused by [CONTACT_83145]4 signaling. ( 40T11, 12 40T). All 
cases that have been genetically characterized to date involve trun cation and missense mutations in the 
intracellular tail of the receptor  that are inherited in an autosomal dominant manner. ( 40T1, 13 40T) This domain 
normally mediates negative regulation of the receptor through G protein-coupled receptor kinase (GRK) -
mediated phosphorylation and beta -arrestin -mediated internalization, providing a potential mechanism for 
the increased signaling that is observed. ( 40T14 40T) Consistent with this, truncated WHIMS receptors have been 
reported to undergo reduced  ligand -dependent receptor down -regulation.( 40T15, 16 40T) One WHIMS patient  
has been identified who lacks CXCR4 mutations , however this individual has  decreased  expression o f 
GRK3, which normally mediates CXCR4 desensitization. ( 40T17 40T) Another family has recently been 
identified with 2 affected members with  a recessive mutation in CXCR2.  Thus, WHIMS can be thought 
of as a disease caused by [CONTACT_83146]4 function  or insufficient CXCR2 function, which  validates the 
fundamental role of these receptors in homeostatic leukocyte trafficking in humans . A mouse model in 
which a human WHIMS CXCR4 mutation (S338X)  was knocked into one mouse CXCR 4 locus 
phenocopi[INVESTIGATOR_83085] .( 40T18, 19 40T) It is possible that 
mutations  in other immunoregulatory gene s may also cause a similar syndrome .  
 The acronym WHIMS  highlights four  clinical manifest ation s of the disease: warts, 
hypogammaglobul inemia, infections, and myelokathexis. Warts are refractory to medical treatment in 
WHIMS  and can evolve into fatal skin and anogenital cancer . Hypogammaglobul inemia is moderate and 
variable.  Nevertheless,  WHIMS patients have been reported to have poor immunologic memory after 
vaccination, and the resul ting low levels of immunoglobul ins may predispose them to frequent 
sinopul monary infections .(
40T20 40T) Perhaps the earliest and most highly penetrant clinical finding is 
neutropenia , usually severe,  which appears to be caused by  [CONTACT_83147] , a 
critical effector cell in innate immunity, in the bone marrow.  Most patients also have panleukopenia. This 
pi[INVESTIGATOR_1103], which is known as myelokathexis, the ‘M’ in WHIMS, further predispos es the patient  to typi[INVESTIGATOR_83086], soft tissue, an d sinopul monary infections. When the absolute neutrophil count (ANC) is  
reduced  below ~500 cells/µL  in patients receiving cytoreductive therapy  for diseases such as cancer , the 
risk of infection  with bacteria and fungi  increases: however , the precise relationship between ANC and 
infection risk in WHIMS has not been defined . During infection in WHIMS patients , neutropenia often 
improves and may temporarily normalize, suggesting that the inhibition of marrow release of neutrophils can be ove rcome in the presence of infection. However, the end resul t of frequent infections in WHIMS 
patients can be serious, with  loss of hearing, teeth, and lung function.   Dental disease consists of HPV 
related oral cancers, severe caries, periodontitis, dental abscesses, and premature tooth loss.  Older 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 20 of 74 
 
 patients can develop severe bronchiectasis resembling cystic fibrosis, and fatal respi[INVESTIGATOR_1399]. Case 
reports of fatal meningitis and Epstein- Barr virus-induced lymphoma in patients with WHIMS  provide 
eviden ce that other immunological problems present in WHIMS patients are clinically significant.( 40T21, 
22 40T) In addition, an increased prevalence of tetralogy of Fallot has been observed in WHIM patients.( 40T23 40T) 
 Current therapeutic recommendations in WHIMS are non-specific, expensive, associated with significant 
side effects, and  based on limited direct clinical data. Daily or every other day injection of G -CSF is 
commonly given to increase the ANC , based on a  placebo -controlled clinical trial that demonstrated G-
CSF safety and efficacy  in reducing the risk of infection in patients with severe congenital neutropenia  
(SCN) of various etiologies .(
40T24 40T) On the basis of this trial, SCN was approved as an indication for G-CSF 
therapy.  However, only a few patients with WHIMS were included in the trial, so that the actual efficacy of G-CSF in modulating clinical endpoints  specifically  in WHIMS is not known. Monthly infusions of 
intravenous immunoglobul in (IVIg) or subcutaneous immunoglobulin are also given to those WHIMS 
patients who have severe hypogammaglobulinemia ; however , its efficacy in this setting has not been 
studied .(
40T1 40T) Anecdotal evidence suggests that together these measures may not affect HPV infection in 
WHIMS patients , nor would they be expected to,  and do not fully prevent infections  (Figure 1) .( 40T25 40T) 
Thus, there is a clear unmet medical need for new treatments in these patients.  For th ese reason s and 
because of expense and side effect considerations (see below) , it is clear that direct studies quantifying the 
clinical efficacy of G-CSF specifically  in WHIMS  as well as development of more specific treatment 
modalities in WHIMS are needed.  
1.2 Description of Study Agent : Mozobil™  (plerixafor ) 
The Food and Drug Administration (FDA) approve d plerixafor  (Mozobil™)  injection in 2008 for use in 
combination with G-CSF to mobilize hematopoietic stem cells to the peripheral blood for collection and 
subsequent autologous transplantation in patients w ith non -Hodgkin’s  lymphoma  (NHL)  and multiple 
myeloma  (MM).( 40T26 40T) Plerixafor  was initially developed as an antiretro viral compound for the treatment 
of human immunodeficiency virus (HIV). ( 40T27 40T) It was found to be a specific and reversible inhibitor of the 
chemokine receptor and HIV co -receptor CXCR4, and its plasma concentrations closely correlated with 
the ability to inhibit CXCR4 HIV viral entry into target cells.  While initial studies showed that it was a 
safe and effective antiviral drug in animals and humans, CX CR4-using virus is not common in initial HI V 
infection and the drug is not orally bioavailable, limiting its usef ulness for treating HIV. However in early 
human studies, it was noted to cause a dramatic and rapid increase in white blood cell count (WBC).  
 This was consistent with other studies in mice showing that CXCR4 is a strong bone marrow retention 
factor for leukocytes in general and neutrophils and CD34
P+ 
Phematopoietic stem cells specifically. This 
prompted successf ul trials of plerixafor  in animals and humans for the purpose of CD34 P+ 
Phematopoietic 
stem cell mobilization. This is a procedure in which apheresis of donor blood is done to separate and 
remove CD34 P+ 
Pcells, which allows for immune system reconstitution after high dose chemotherapy for 
cancer. Plerixafor  is effective either by [CONTACT_83148] -stim ulating factor 
(G-CSF), which is the agent that has traditionally been used for this purpose. In Phase III clinical studies 
that led to its licensure in the US, it was found that there was a dramatic, statisti cally significant increase 
in the percentage of diffic ult to mobilize (because of prior chemotherapy) individuals who reached the 
target number of cells collected when plerixafor  was used with G-CSF compared to when  G-CSF was 
used alone. ( 40T28, 29 40T) 
 Clinical Pharmacology / Mechanism of Action: Plerixafor  is a specific antagonist of the CXCR4 
chemokine receptor and blocks binding of its cognate ligand, stromal cell -derived factor -1 (SDF -1 also 
known as CXCL12). Both SDF-1 and CXCR4 are recognized to play a role in the trafficking and homing 
of human hematopoietic stem cells (HSCs) to the marrow compartment. Once in the marrow, stem cell CXCR4 can act to help anchor these cells to the marrow matrix, either directly via SDF-1 or through the 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 21 of 74 
 
 induction of other adhesion molec ules. Treatment with plerixafor  resulted in leukocytosis and elevations 
in circ ulating HSC  in mice, dogs, and humans.  
 
Pharmacokinetics: Pharmacokinetic studies in normal volunteers and cancer patients have shown that 
plerixafor is rapi[INVESTIGATOR_83087] (SQ ) injection.( 40T10, 30 40T) Peak plasma concentration is 
observed at 30 -60 minutes after a single 0.24 mg dose and the half -life has been estimated at 
approximately 5 hours. The drug is eliminated  through the kidneys with 70% excreted unchanged in the 
urine in [ADDRESS_90602] found the receptor to be critical for several aspects of embryogenesis and immune system development.(8,31,32)  
Adverse Reactions: The data described herein reflect 2 randomized studies in patients with NHL and 
MM, in which 301 patients treated with plerixafor  in combination with G -CSF were compared to 292 
patients who were treated with placebo and G-CSF.(
40T28,29 40T) Side effects attributed to the drug were 
relatively minor and consisted of mild injection site reactions and gastroi ntestinal complaints . 
( 40TAppendix B 40T) In partic ular, the most common adverse reactions (> 10%) reported in patients who 
received plerixafor  in conjunction with G -CSF were diarrhea, nausea, fatigue, injection site reactions, 
headache, arthralgia, dizziness, and vomiting.  
 
UGastrointestinal complaints U: Nausea, vomiting, and diarrhea were frequently reported in cancer patients 
treated with both plerixafor  and G -CSF, but also may be attributable to the chemotherapy, the apheresis, 
or the underlying disorder  as these have not been a problem in WHIM S patients treated to date. 
 
UInjection site reactions U: In the randomized studies, 34% of patients with NHL or MM had mild to 
moderate injection site reactions at the site of subcutaneous administration of plerixafor .(28,29 ) These 
included erythema, hematoma, hemorrhage, induration, inflammation, irritation, pain, paresthesia, 
pruritus, rash, swelling, and urticaria.  In contrast, i n 2 studies of the drug in WHIM S patients, injection 
site reactions occurred but consisted only of small, self-resolving areas of erythema and pruritus  occurring 
mainly at doses of 0 .08 mg/kg and above. ( 40T3, 4 40T) In the patients treated for 6 months with low doses (0.01-
0.04 mg/kg) no injection site reactions were observed .(5) 
 
UOther adverse events: U Mild to moderate systemic reactions were observed in fewer than 1% of patients in 
cancer studies approximately 30 minutes after  plerixafor  administration. These events included one or 
more of the following: urticaria, periorbital swelling, dyspnea, hypoxi a, vasovagal reactions, orthostatic 
hypotension, and/or syncope . Symptoms generally responded to treatments (e.g., antihistamines, 
corticosteroids, hydration, or supplemental oxygen) or resolved spontaneously  (Appendix B ), and have 
not been observed in studies of WHIMS patients.  
1.2.[ADDRESS_90603] demonstrated that plerixafor  is specific for CXCR4 and is a reversible inhibitor of 
the natural ligand's (SDF -1, aka CXCL12 ) ability to bind the receptor.  Plerixafor  has a very similar ability 
to bind and block the signaling of  both wild type and WHIM variants of CXCR4.( 40T2 40T) Long-term 
administration to mice, rats, and monkeys was found to be safe; however, in high doses (10 times > the highest human dose) in pregnant rats, the drug was found to be teratogenic causing fetal mortality. Also in rats, increased spleen weight was observed after 2 to 4 weeks of daily administration at high doses – 
[ADDRESS_90604] human dose  (Appendix B). 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 22 of 74 
 
 1.2.2 Summary of Relevant Clinical Studies 
Plerixafor  in combination with G -CSF has been used in more than 980 patients enrolled in 16 clinical 
studies for the purpose of stem cell mobilization as reported by [CONTACT_3455], Genzyme/[COMPANY_011]  Corp, 
to the FDA. In one  randomized study of 298 patients with NHL  where all patients were given 0.24 mg/kg 
of the drug subcutaneously  daily for 1 to 7 days (median, 2 days), 59% of those who received the drug 
combination were able to achieve the collection goal of 5 million CD34+ cells/kg versus only 20% who received G-CSF alone (p<0.001).(
40T28 40T) In a second randomized study, [ADDRESS_90605] and 72% achieved the collection goal of 6 million CD34+ cells/kg versus 
only 34% of those who received G -CSF alone (p<0.001).( 40T29 40T) In Phase I studies by [CONTACT_83149] t, et al and 
Dale, et al ., 9 adult WHIM S patients were treated with a dose escalation of plerixafor  up to the FDA 
approved dose of 0.24 mg/kg/d and were found to rapi[INVESTIGATOR_83088].( 40T3, 4 40T)  The lowest dose, 0.02 mg/kg/d , was able to increase the neutrophils to 
greater than 500 cells/µL  of blood which is considered the boundary below which an increased risk of 
bacterial and fungal  infection may occur .  One of the 9 had to stop the dose escalation at 0.08 mg/kg 
because of development of a n acute exacerbation  of chronic bronchitis and possible pneumonia  ( 40T4 40T), but 
both studies concluded that the drug was safe and effective and that this was proof of principle that 
antagonism of CXCR4 co uld reverse panleukopenia.  However, these studies left open the question as to 
whether long- term, low dose therapy wo uld be practical, safe, and clinically effective.  We have 
compl eted a 6 -month study of 3 ad ult WHIMS patients given 0.01 -0.02 mg/kg twice/day and found that 
the leukocyte mobilization effects were durable and that the drug was safe for administration  up to 6 
months .(5).  
 Moreover, the frequency of infection was reduced on plerixafor as compared to retrospective data mined for the three years before starting therapy and prospective data collected for one year after ending therapy.  
No new warts occurred during treatment and multiple existing warts improved or resolved. Although 
these results are encouraging, the small number of patients studied, limited duration of drug treatment, 
and retrospective mining of control data leave open to question whether plerixafor is truly efficacious for clinical outcomes in WHIMS .  The goal of the current study is to answer this question choosing as the 
primary endpoint the severity of infections compared between  the plerixafor  treatment arm and the 
comparator G-CSF treatment arm using a double -blind ed, crossover design .  G-CSF is required as a 
comparator because of its approved use in patients with SCN. 
1.3 Description of Comparator Treatment: G -CSF  
G-CSF is FDA -licensed and the standard of care for severe chronic neutropenia, and will be used as the 
control or comparator drug in this study. (
40T24 40T) (see 40TAppendix C 40T) G-CSF is a recombinant human protein 
produced in E. coli that is identical in amino acid sequence with the exception o f an additional N-terminal 
methionine to a naturally occurring cytokine  made by [CONTACT_83150], fibroblasts, and endothelial 
cells.  G-CSF acts on specific receptors to regulate the proliferation and differentiation of neutrophil 
progenitor s, and augment s the bone marrow release and  function of mature neutrophils.  It has minimal 
effects on other hematopoietic cell types.  Its effect on bone marrow release of neutrophils is mediated in part by [CONTACT_83151]12 availability at CXCR4. 
1.3.1 Summary of Relevant Clinical Studies  
In Phase I studies involving 96 subjects with no myeloid malignancies‚ G- CSF administered at doses of 1 
to 70 µg/kg/day resulted in a dose -dependent increase in circulating neutrophil counts. (33-35 ) Neutrophil 
counts returned to baseline within [ADDRESS_90606] subjects receiving G -CSF; however‚ 
the percentage of monocytes in the differential count remained within the normal range. In all studies t o 
date‚ absolute counts of eosinophils and basophils were within the normal range following administration of G-CSF. Increases in lymphocyte counts following dosing with G -CSF have been reported in some 
healthy individuals and subjects with cancer.  Daily administration of G -CSF has been shown in a 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 23 of 74 
 
 randomized Phase III trial to be safe and effective in children and adults with severe chronic neutropenia, 
resulting in sustained increases in the neutrophil count and decreases in infection-related morbidity.( 40T24 40T) 
In particular‚ daily treatment with G -CSF led to significant beneficial changes in the incidence and 
duration of infection‚ fever‚ antibiotic use‚ and oropharyngeal ulcers  in this setting.(24) The lower 
incidence and duration of infections was associated with decreased epi[INVESTIGATOR_68043], diarrhea‚ nausea‚ fatigue‚ and sore throat. In that study, the G- CSF dose was adjusted to maintain a median ANC 
between 1500  and 10‚000 cells/mm
P3
P. Overall‚ response to G-CSF was observed in 1 to 2 weeks. The 
median ANC after 5 months of G-CSF therapy was 7460/mm P3
P (range, 30/mm P3 
Pto 30‚880/mm P3
P).  
 Mild -to-moderate bone pain was reported in approximately 33% of subjects with severe chronic 
neutropenia  treated with G-CSF in clinical trials. (see 
40TAppendix C 40T) This symptom was readily controlled 
with non- narcotic analgesics. Generalized musculoskeletal pain was also noted in a higher frequency of 
subjects treated with G-CSF. Palpable splenomegaly was observed in approximately 30% of subjects. 
Abdominal or flank pain was observed infrequently, and thrombocytopenia (<50‚000/mm P3
P) was noted in 
12% of subjects with palpable spleens. Fewer than 3% of all subjects underwent splenect omy‚ and most 
of these had a pre-study history of splenomegaly. Fewer than 6% of subjects had thrombocytopenia during G -CSF therapy‚ most of whom had a pre -existing history of the condition. Thrombocytopenia was 
managed by [CONTACT_83152] G -CSF . An additional 5% of subjects had platelet 
counts between 50‚000/mm
P3
P and 100‚000/mm P3
P, with no associated serious hemorrhagic sequelae. 
Epi[INVESTIGATOR_83089] 15% of subject s treated with G- CSF‚ which was associated with thrombocytopenia 
in 2%  of the subjects. Anemia was reported in approximately 10% of subjects‚ but, in most cases, it 
appeared to be related to frequent diagnostic phlebotomy‚ chronic illness, or concomitant medications. Other AEs infrequently observed and possibly related to G-CSF therapy were injection site reaction‚ rash‚ hepatomegaly‚ arthralgia‚ osteoporosis‚ cutaneous vasculitis‚ hematuria/proteinuria‚ alopecia‚ and 
exacerbation of some pre-existing skin disorders (e.g.‚ psoriasis). Cytogenetic abnormalities, 
transformation  to myelodysplastic syndrome (MDS), and acute myeloid leukemia (AML) have been 
observed in subjects treated with G-CSF for severe chronic neutropenia.  
 
As of [ADDRESS_90607] marketing surveillance study of 531 
subjects with severe chronic neutropenia who had an average follow-up of 4 years. Based on analysis of 
these data, the risk of developi[INVESTIGATOR_83090]. A life -table analysis of these data revealed that the cumulative risk of developi[INVESTIGATOR_83091] 8
Pth
P year of treatment with G-CSF in subjects with congenital neutropenia 
was 16.5%, which represents an annual rate of approximately 2%. Cytogenetic abnormalities, most common ly involving chromosome 7, have been reported in subjects treated with G-CSF who had 
previously documented normal cytogenetics. It is unknown whether the development of cytogenetic abnormalities, MDS, or AML is related to chronic daily administration of G -CSF or to the natural history 
of congenital neutropenia. It is also unknown if the rate of conversion in subjects who have not received G-CSF is different from that of individuals who have received it. Routine monitoring through regular complete blood coun t (CBC) is recommended in all subjects with severe chronic neutropenia.  
1.[ADDRESS_90608] that long  term, high dose G -CSF therapy 
may be associated with the development of leukemia and myelodysplasia in SCN patient s.(
40T36 40T) Whether 
or not this would occur in WHIM S patients is currently unknown, but is one reason to consider alternative 
therapi[INVESTIGATOR_014].  In addition, patients have been described who due to G -CSF receptor mutations or the 
development of anti -G-CSF antibodies fail to respond to G-CSF with an increased ANC. ( 40T37 40T)  In 
addition, our anecdotal experie nce is that WHIM S patients experience severe bone pain with the normal 
dosing of G -CSF perhaps due to their increased retention of mature neutrophils in the marrow 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 24 of 74 
 
 (myelokathexis). Lastly, G -CSF is not an effective treatment for warts, the signature [CONTACT_83201] , 
which might be better addressed with mechanism -based therapy such as plerixafor .   
 
Our Phase 1  study  has provided preliminary evidence that low dose plerixafor b.i.d. is safe and effective 
over 6 months in mobilizing leukocytes to the blood, reducing infection frequency (Figure 1) and 
reducing wart burden; however, thi s stud y was not designed, controlled  or powered to establish efficacy 
of plerixafor treatment for the main clinical endpoints  in the disease (recurrent infections and warts) or to 
compare its efficacy  to G-CSF, the FDA approved  therapy  for SCN .(5)  
1.[ADDRESS_90609] experienced a worsening rash (psoriasis-like ) beginning a week after commencing the [ADDRESS_90610]
P study 
drug and the symptoms resolved after switching to the alternate study drug  and topi[INVESTIGATOR_83092].  
1.5.2 Joint Pain (Arthralgia) and a n Incident of Reactive Arthritis  
Some  subjects with a prior history of  joint pain (arthralgia  or arthritis ) prior to  enrollment experience  a 
recurrence or worsening of their symptoms  with G -CSF and/or with the study drug(s) .  However, one 
subject  who had no prior history of joint pain or G-CSF treatment, experienced pain and swelling in his 
wrist, hands, and knees and had  to be  discontinued from both study drugs and treated with oral steroids. 
Soon after the pain began , the subject tested positive for urethral chlamydia  which causes reactive 
arthritis .  Thus it may be that the subject’s symptoms were exacerbated by [CONTACT_83153] . 
 
  
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 25 of 74 
 
  
 
 
 
Figure 1 :  Plerixafor May Reduce Infection Incidence in Patients with WHIMS. 
The data for each patient are presented in separate columns. Each infection is represented as a  
dot and plotted by [CONTACT_83154]. The time on 
plerixafor is bounded by [CONTACT_83155]. Note that data for P2 were unavailable for the 12 month period marked by [CONTACT_83156]. For P3, the hatched box represents a gap in plerixafor administration for the purpose of clinical care.  G- CSF was administered to patients P1  and P2  
both before and after plerixafor treatm ent, whereas P3 received G- CSF for ~1 month after 
plerixafor.
 
  

Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 26 of 74 
 
 2 STUDY OBJECTIVES  
2.1 Primary Objective  
Compare the severity of infection during treatment with plerixafor and G -CSF. 
2.2 Secondary  Objectives 
1) Compare component measures of infections.  
2) Measure the control of warts with plerixafor  versus G-CSF. 
3) Demonstrate the safety of plerixafor  and G -CSF as long -term therapy . 
4) Compare the symptoms of chronic infections.  
5) Compare q uality of life (QOL) . 
6) Compare drug tolerability  and subject  drug preference. 
7) Compare the increase of leukocyte levels from baseline.  
2.[ADDRESS_90611] is not already receiving it , and dose is adjusted if necessary  to achieve an ANC between 
500-15 00 cells/μL  of blood . Subjects start completing a daily Memory Aid  submitting to the NIH-CC 
once per  week . The Memory Aid  includes their  G-CSF treatment , any new or persistent symptoms, use of 
prophylactic antibiotics , and IVIg treatments. Subjects also report use of any other medication s, incidence  
and duration of fever , new infections, incidence &  duration of antibiotic treatments, and any 
hospi[INVESTIGATOR_602]. Another purpose of this evaluation period  is to ensure that subjects are able to comply  
with required  study procedures . At completion of the evaluation period, subject s are randomized to begin 
either plerixafor  or G-CSF treatment .  Subjects shall ho ld G-CSF 2 days  in advance of  commencing study 
medication . The next phase of the study is the Equilibration Period of 8 weeks, during which the blinded 
study drug dose is adjusted for a target  ANC of 500-1500 cells/μL  with the ANC count  measured  
approximately every [ADDRESS_90612]’s local medical facility . After this, the study drug dose is 
continued for 52 weeks, during which the dose may be adjusted to maintain the ANC between approximately 500-7500 cells/μL .  Also, in this treatment period  clinical events are counted and subjects 
visit the NIH-CC approximately every [ADDRESS_90613] blood drawn for CBC/ANC prior to the 
morning dose of study drug and for treatment of new or worsening infections. CBC/ANC is monitored at the NIH-CC for safety and the need for additional dose adjustments as determined by [CONTACT_9532] [INVESTIGATOR_83093] . Subjects unable to tolerate a study 
drug will  be switched to the alternate study agent  according to rules specified below in the Statistics 
(section 14).  
 
Plerixafor  vs. G -CSF in WHIMS – Version 6.[ADDRESS_90614] s are 
offered the opportunity to restart G- CSF therapy.  There is then a 1-month G-CSF Equilibration  and 
subjects continue to maintain their diaries  and to visit their local medical facility for blood draws 
approximately every two weeks. A study completion  visit at the NIH-CC occurs approximately 5 to 6 
months after the end of the second year of treatment. 
3.2 Study Endpoints 
3.2.1 Primary Endpoint 
The primary endpoint is infection severity, which is measured as a composite of multiple weighted 
parameters according to rules defined in 40TAppendix D 40T.  
3.2.2 Secondary Endpoints  
1) Component measures of infections ; incidence and duration of infections, fevers, antibiotic treatments, 
and hospi[INVESTIGATOR_059] . 
2) Control of warts as defined by [CONTACT_2669] a 50% reduction in numbers, areas or size of existing warts and 
by [CONTACT_83157]. 
3) Blood count and immunological param eters.  
4) Clinical measures of chronic i nfections.  
5) Treatment side effects,  
6) Quality of life scores.  
7) Treatment preference.  
3.2.[ADDRESS_90615] Selection and Recruitment Plan  
The study is open to patients  with WHIMS from 10 -75 years of age who may benefit from the study’s 
proposed treatments. WHIMS is a rare genetic disease with approximately [ADDRESS_90616] a cohort of 24 patients , with 50% of these patients  accrued in [ADDRESS_90617] to screen 30 patients (accrual ceiling ) in order to 
enroll and randomize 20 patients.  
4.2  Inclusion Criteria  
Subjects are eligible to enter the study if they meet all of the following criteria: 
1)  Age > 10 and <75 years. 
2) Heterozygous mutation in the C -tail of CXCR4 in addition to  a clinical diagnosis of WHIMS.  
3) Documented neutropenia with a baseline ANC below 1500 cells/μL  of blood. 
4) History  of severe and/or recurrent infection s. 
5) Willingness to interrupt G -CSF medication , 2 days  prior to study drug injection.  
6) Must have a local  medical provider for medical management.  
7) Must be willing to provide blood, plasma, serum, and DNA samples for storage. 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 28 of 74 
 
 8) All study subjects must agree not to become pregnant or impregnate a female.  Women of 
childbearing potential must  agree to take appropriate steps to avoid becom ing pregnant for the  
duration of the study. Participants in whom pregnancy is biologica lly possible must  use at least [ADDRESS_90618] continue 
contraception until 5 months after stoppi[INVESTIGATOR_35648]:   
• Male or female condoms  with a spermicide, 
• Diaphragm or cervical cap with spermicide, 
• Intrauterine device, 
• Contraceptive pi[INVESTIGATOR_43516], Norplant, Depo-Provera or o ther FDA-approved contraceptive,  
• Male partner with vasectomy and documen ted aspermatogenic sterility.  
9) Willingness to comply with the study medications, visits, and procedures, a s deemed necessary by [CONTACT_28824]  (PI).  
4.[ADDRESS_90619] will not be enrolled in this study:  
1) Neutropenia due to maturation defects in the myeloid lineage or a type of neutropenia, which in the investigator’s opi[INVESTIGATOR_1649], is unlikely to improve from the medication administered in this study.  
2) Pregnant or breast-feeding  women.  
3) Known hypersensitivity  to plerixafor, G-CSF, or any components of the products.  
4) Predisposition to or history of life-threatening cardiac arrhythmia. 
5) Requiring dialysis or having markedly impaired renal function with a Creatinine Clearance ( CrCl) 
<15 mL/min  (
40TAppendix E 40T). 
6) Condition that in the investigator’s opi[INVESTIGATOR_83094] a  subject  at undue risk by [CONTACT_83158] . 
4.[ADDRESS_90620] prior to receiving
P 
Pplerixafor .   
4.5 Justification for Exclusion of Children < 10 Years of Age   
Subjects younger than 10 years of age will be excluded from the study. Altho ugh WHIMS  is a rare 
congenital immu nodeficiency disorder that affects all age groups, plerixafor  has known effects on fetal 
development in animal models .(8,32,38)   These are related to early localization of cells during fetal 
development ; therefore, we feel that age [ADDRESS_90621] been treated with single high dose (0.24 mg/kg/d) 
plerixafor  for stem cell mobilization without serious side effects and chronic G-CSF use is safe in 
children. ( 40T39,40 40T)   
5 STUDY AGENT AND INTERVENTIONS  
5.1 Drug Acquisition 
5.1.1 Plerixafor : Provided by [CONTACT_83159]-approved for hematopoietic stem cell mobilization in cancer  and is the study drug. It is 
manufactured  by [CONTACT_83160]/[COMPANY_011] Corp., Cambridge, MA , [LOCATION_003]. The manufacturer supplies the drug , 
which is investigational in this study, a t no cost .  
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 29 of 74 
 
 5.1.2 G-CSF : Obtained Commercially  
G-CSF is an FDA-approved drug manufactured by [CONTACT_44908] n and is the comparator drug in this study 
because it  is FDA-approved for the treatment of SCN.   Drug will be sourced commercially and purchased 
per the NIH-CC policy.  
5.2 Disposition and Dispensation 
The study drug and the comparator drug are dispensed through the NIH-CC ’s pharmacy.  
5.2.1 Form ulation, Packaging, and Labeling  
[IP_ADDRESS]  Plerixafor  Packaging from M anufacturer   
Plerixafor  injection  is a sterile, preservative-free, clear, and colorless to pale yellow isotonic solution for 
subcutaneous injection. Each mL of the sterile solution contains 20 mg of plerixafor . Each single -use vial 
is filled to deliver 1.2 mL of the sterile s olution conta ining 24 mg of plerixafor  and 5.9 mg of sodium 
chloride in water for injection . Storage at room temperature is recommended at 25 °C (77°F) with 
excursions from 15° C-30° C (59°F - 86°F).  
[IP_ADDRESS]  Plerixafor  Repackaging for Study and/or Shipment to Study Participants  
Plerixafor  vials from the manufacturer will be repackaged by [CONTACT_83161], Inc  into pre-set low-dose 
volumes between 0.01-0. [ADDRESS_90622]  will contain a  dose rang ing between  0.01-0.04  mg/kg. The upper limit dose of 0.04 mg/kg in this 
study is low compared to the FDA-approved dose for HSC mobilization (0.24 mg/kg)  and was set at this 
level because our treatment goal is to reduce CXCR4 signaling to normal from 2X normal, the typi[INVESTIGATOR_83095] S variants of CXCR4, not to zero.  Syringes will be shipped  periodically to the subject 
who will store them at refrigeration temperature until injected . 
[IP_ADDRESS]  G-CSF Packaging from Manufacturer  
G-CSF is a sterile‚ clear‚ colorless‚ preservative-free liquid for parenteral  administration containing 
filgrastim at a specific activity of 1.0 ± 0.6 x 10 P8
P U/mg (as measured by a cell mitogenesis assay). The 
product is available in single -use vials and  prefill ed syringes. The single-use vials contain either 300 µg  
or 480  µg  filgrastim at a fill volume of 1.0 mL or 1.6 mL respectively.  Refrigerated storage is 
recommended at 2 °C - 8°C (36°F - 46°F), but vials  can be left at room temperature for up to [ADDRESS_90623] sunlight.  
[IP_ADDRESS]  G-CSF Re packaging for  Study and/or Shipment to Study Participants  
G-CSF vials from the manufacturer will be repackaged  by [CONTACT_83161], Inc  into pre-set volumes of 
between 0.[ADDRESS_90624]  will range between  0.01-2. 0 µg/kg. If randomized to the plerixafor  arm, the dose may be 
temporarily reduced during the transition to accommodate potential residual synergistic effects of the 
drugs between the treatment arms. Syringes will be shipped  periodically to the subject, who will store 
them at refrigeration temperature until injected. 
5.2.2 Labeling of Study Drug  
Sy
ringes containing the r epackaged  plerixafor  or G-CSF shall be labeled per NIH Pharmacy  policy. A n 
investigational use statement (“Caution: New Drug – Limited by [CONTACT_4496] [US A] Law to Investigational 
Use”)  will also be labeled.  
5.[ADDRESS_90625] 6 months . Refer to the 
package inserts ( 40TAppendix B 40T & 40TAppendix C 40T) and the abstract from the American Association of 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 30 of 74 
 
 Pharmaceutical Scientists conference (
40Thttp://abstracts.aaps.org/Verify/aaps2013/postersubmissions/T2294.pdf 40T).  
5.3.[ADDRESS_90626]  home address on a periodic basis with appropriate packaging to 
prevent ext remes of temperature.  
5.3.2 Shipment  to Pa rticipants'  Home  
Subjects receive their study dr ug approxima tely once a month or as required. Shipments are prepared by 
[CONTACT_83162] a rapid courier  or provided to subjects on their visits to the NIH-CC.  
5.[ADDRESS_90627] Memory Aid: Injection Site, Injection Volume, Adverse React ions 
Participants are asked to record the quantity injected, the site of injection, and any adverse reaction from 
the injection  (see 40TAppendix F 40T). Subject s are instructed to seek medical attention and  inform study staff or 
the NIH-CC of any adverse events that are life threatening, require immediate medical attention, or limit 
their ability for  self-care.  
5.[ADDRESS_90628]’s Absolute Neutrophil Count  (ANC)  to maintain the 
pre-morning dose  ANC count at approximately  between  500-1 500 cells/μL  during the Equilibration 
period. Consideration of concurrent infection or other factors that might increase the ANC will be 
factored into ongoing clinical decisions to adjust the study medication dose.  Blinding will be maintained by [CONTACT_83163] [INVESTIGATOR_83096]-blinded select the drug, dose, and shipment based on the subject ’s randomization.  
5.[ADDRESS_90629] Accountability Procedures  
5.6.1 Plerixafor  
The PI [INVESTIGATOR_83097],  receipt, and return of  plerixafor  from /to the manufacturer.  NIH-CC’s  
pharmacy is responsible for storing , repackaging,  labeling , and shippi[INVESTIGATOR_83098] .  
5.6.2 G-CSF  
NIH-CC’s  pharmacy is responsible for sourcing and order ing G-CSF from suppliers and for repackag ing, 
labeling , and shippi[INVESTIGATOR_007] G-CSF to the subject .   
6 STUDY SCHEDUL E AND ACTIVITIES  
A schedule of procedures and evaluation  for the study is shown in  40TAppendix A 40T. 
6.1 Recruitment   
Candidates are interviewed to confirm their diagnosis of WHIMS  and provided a copy of the study’s 
Informed Consent . A history of recurrent infections and neutropenia , documented CXCR4 muta tion, or a 
newly identified mutation made by [CONTACT_83164].  Subject s interested in the study are sched uled for a screening visit at NIH-CC.  
Plerixafor  vs. G -CSF in WHIMS – Version 6.[ADDRESS_90630] s undergo the following procedures : 
• Pregnancy test for women of childbearing potential.  
• Viral Screen: HIV,  HTLV -1 and 2, Hepatitis  B and C. 
• CBC with diff, Chemistries (Acute Care Panel, Creatine Kinase, Hepatic Panel, Mineral Panel, 
Total Protein, Lactate Dehydrogenase, Uric Acid), erythrocyte sedimentation rate (ESR ). 
• Prothrombin time (PT), partial thromboplastin time (PTT), Vitamin B -12 & Folate, and Urinalysis. 
• Echocardiogram  (within the last 5 years for adult ) must be reviewed and approved by [CONTACT_978].  
• EKG.  
6.2.[ADDRESS_90631]’s overall health and safety in the study:  
• Weight.  
• Vital signs  (temperature, heart rate, and blood pressure).  
• Medical History  including history of infections and warts.   
• Medication History  including allergies, concomitant medication s, IVIg & G -CSF treatments, and 
prophylactic antibiotics. 
• Contraception counseling as appropriate.  
• Physical Exam . 
• Encourage subjects and their local providers to contact [CONTACT_83165] [INVESTIGATOR_83099] 
(or suspected onset) of an infection.  
6.[ADDRESS_90632]’s health  and ensure they are trained and prepared prior to 
commencing the first study dose. This Initial Evaluation and Baseline Assessment  period is targeted  to be 
about [ADDRESS_90633] study dose  (Section 6.4). 
Procedures for baseline assessment may be completed  anytime prior to the first dose, furthermore some 
labs may be drawn and analyzed at the  subject’s local medical facility  (Section 6.3.12 ). 
6.3.[ADDRESS_90634]’s immunological markers:  
• Quantitative Immunoglobulins 
• Leukocyte Phenotypi[INVESTIGATOR_007]  
• Antibody levels for Diphtheria and Tetanus.  
6.3.2 Evaluation s: Dermatology, GYN, Dentistry, ENT, Audiology , and Clinical Photography  
Due to the prevalence of infections and  the risk of  HPV in patients with WHIMS, dermatologic, 
gynecologic, dental, ENT, and audiology evaluations , and photographs of infections and warts on the 
body surface,  will be arranged  for subjects prior to commencing their  first study treatment, and at the end 
of each their study drug treatments periods. These evaluations are not mandatory; a subject may refuse to 
participate in any of the assessments. These evaluations are not meant to replace care provi ded by a  
subject’s local provider(s).  
6.3.3 Additional Evaluations if Clinically Indicated (e.g. PFT and CT of Chest and Sinus)  
Some of our WHIMS patients experience frequent respi[INVESTIGATOR_83100]. For these subjects, pulmonary function tests (PFT), sputum 
Plerixafor  vs. G -CSF in WHIMS – Version 6.[ADDRESS_90635] and sinus, as well as a pulmonary consult with possible bronchoscopy 
may be arranged to treat and evaluate the status of their infections. These evaluations are n ot mandatory; a 
subject may refuse to participate in any of the assessments.  
6.3.4 Baseline Measure of Bone Density and Spleen Size  
• Dual -energy x -ray absorptiometry (DEXA)  scan. 
• Ultrasonography of the spleen.  
6.3.5 Research  Blood  
Research blood  will be collected as required and  may include the following:  ~10 mL of EDTA anti-
coagulated blood (1 purple top), ~10 mL of serum (1 tiger top), and 30-60 mL of heparinized blood (3-6 
green tops).  The blood will be collected for various purposes, including DNA/RNA isolation, EBV-
transformed cell line creation, serum/plasma storage, flow cytometry , cytokine measurements, and drug 
levels.  
6.3.6 Wart and/or Skin B iopsy  (optional)   
Wart and or skin biopsies may be requested for diagnosis and research from subjects but will be optional. 
An experienced provider  will perform the procedure. Local anesthetics will be used for the biopsy site; no 
conscious sedation or general anesthesia will be given. The risks of skin/ wart biopsy include local pain, 
bleeding, infection, and the potential for scar and keloid formation. Antibiotics and oral analgesics will be 
used to manage pain and infection. The histologic response to plerixafor  offers generalizable knowledge 
about the pathophysiology and treatment of this condition. 
6.3.7 Bone Marrow Biopsy  (optional)   
Subjects will have the option of having bone marrow biopsy/aspi[INVESTIGATOR_83101], which could be done either as out patient  or inpatient. L ocal anesthetics will be used for the biopsy site and IV 
conscious sedation may be offered to subject s for comfort; these agents may result in transient local 
discomfort initially and occasionally be associated with allergic reactions. General anesthesia will only be 
given if the participant is admitted for the procedure. The primary risks of bone marrow biopsy include 
local pain, bleeding, and infection. Antibiotics and oral analgesics will be used to manage pain and infection  if necessary . 
6.3.8 Quality of Life Assessment of Period Prior to the Study  
Subjects will participate in the quality of life  surveys ( Section 7.9) with the first survey conducted  early in 
the Initial Evaluation and Baseline Assessment period, after a subject has been screened, in order to 
reflect their experience prior to interventions caused by [CONTACT_15365].  
6.3.[ADDRESS_90636]’s use of IVIg and prophylactic antibiotics 
will be tracked in the subject Memory Aid  (Section 6.3.12). 
6.3.[ADDRESS_90637] many of the WHIM S subjects 
enrolled in this study to be on daily or every other day treatment with G-CSF prior to enrollment. For this 
study, we need to determine the Minimum Effective Dose (MED) of  b.i.d G-CSF injection to achieve an 
ANC of  500-1 500 cells/μL. Enrollees , not on b.i.d G-CSF or with an ANC less than the lower limit of the 
target ANC range will have G-CSF initiated or adjusted  in this period prior to being randomized.   
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 33 of 74 
 
 6.3.11  Preparing  for Study Drug Shipment s and Study Drug Administration at Home  
Subjects will be  trained on receiving, storage, preparation, and self-administration of the  
study/comparator drugs . These procedures are reviewed and customized as necessary  for each subject  at 
their screening visit.  To verify the practicability of these  procedures, a medication  kit containing the 
comparator drug (G -CSF) may be shipped to the subject  in this period.  
6.3.[ADDRESS_90638] ample time to practice and become proficient at completing and submitting the ir clinical Memory Aid  (Sections 7.4-7.6). The 
information collected will assist in monitoring  a sub ject’s response to b.i.d G-CSF (S ection 6.3.10) and 
their proficiency at completing the Memory Aid . Subjects will not be randomized to commence study 
treatment unless they demonstrate two successful submissions and express confidence at completing the Memory Aid .  
6.3.[ADDRESS_90639]’s Home Locale 
Subjects requir e access to a local medical facility  so that we can  monitor their response , in between visits 
to the NIH-CC, to home administration of  G-CS F or plerixafor.  Labs from these facilities will be 
requested  during initial e valuation to determine the optimum dose for  b.i.d G-CSF (S ection 6.3.10) , 
during  equilibration  to adjust their study dose (Section 6.5.1), and during treatment  to ensure that their 
response to the study drug dose remains optimum (Section 6.6.2 ). We will work with each subject to 
ensure that  a local medical facility  is available for these purposes and all required study procedures are 
paid by [CONTACT_18121].  
6.[ADDRESS_90640] Study Dose  
After completing  their evaluation and baseline assessment ( Section 6.3), subjects are random ized to start 
with either plerixafor or G -CSF for the first year to be followed by [CONTACT_83166] [ADDRESS_90641] Study/Comparator Dose (at least [ADDRESS_90642] dose ) 
All b aseline assessments of infection  and warts shall  be completed prior to a subject  receiving their first 
study /comparator drug injection. Subjects  withh old their G-CSF or study/comparator drug injection  at 
least [ADDRESS_90643] day of the study /comparator drug injection (Day 0 ).  
6.4.2 Assess m ent of Overall Health (within [ADDRESS_90644] dose)  
A clinical assessment similar to what was conducted at baseline (S ection 6.2.2 ) should be repeated within 
[ADDRESS_90645] study dose.  
6.4.3 Confirm Study Drug Shipment/Injection, Memory Aid , Local Labs, and Reporting 
Infections  
Review and confirm with the subject the processes established for receiv ing, stor ing, or administering  the 
study drug, complet ing and submitting the Memory Aid , and  obtaining blood draws at their local medical 
facility . Review and confirm process for reporting infections, diagnosis, and forwarding the information 
from th eir local provider.  
6.4.[ADDRESS_90646] Study/Comparator Dose  
• CBC with diff, Chemistries (Acute Care Panel, Creatine Kinase, Hepatic Panel, Mineral Panel, 
Total Protein, Lactate Dehydrogenase, Uric Acid), erythrocyte sedimentation rate (ESR ). 
• Quantitative Immunoglobulins   
• Leukocyte Phenotypi[INVESTIGATOR_007]  
• Pregnancy test for women of childbearing potential  
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 34 of 74 
 
 • Research Blood . 
6.4.[ADDRESS_90647] Study/Comparator Dose  (Day 0) 
The subject  administers the morning dose  at NIH-CC while being observed by [CONTACT_83167]-administered  subcutaneous (SQ) injection .  
[IP_ADDRESS]  Prior  to Injecti on 
• Orthostatic  measurements ( i.e. pulse and  blood pressure  taken in the supi[INVESTIGATOR_050], sitting, standing , 
position approximately 2 minutes apart ) within 1 hour  prior to  study drug injection.  
• Labs: CBC with diff , chemistries, and ESR  (optional if previous labs are within 24h).  
• Research Blood  
[IP_ADDRESS]  After Study Drug Injecti on 
• Orthostatic measurements 60 m in (+/- 20 min) after study drug injection.  
[IP_ADDRESS]  Procedures P rior to Leaving NIH -CC 
• Subjects ar e supplied with study drug kit and a supply of the study/comparator drug.  
• Counse l subject s with symptomatic or measured orthostasis (decrease in blood pressure > 20 mm 
Hg systolic or increase in pulse >20 /min) to exercise additional caution with home dosing.  
• Confirm the schedule and procedure for CBC blood draws at the subject’s local medical facility.  
• Confirm p rocedures for subject  receipt of study /comparator drug, storage, and administration . 
• Confirm procedures for subject submission of reports on newly diagnosed infections and 
treatments by [CONTACT_83168]. Encourage subjects to contact [CONTACT_83169] [INVESTIGATOR_83102] (or suspi[INVESTIGATOR_2798]) of an infection. 
• Confirm Subject Memory Aid : completion, schedule, and method of submission to NIH-CC. 
6.5 Equilibration Period for the Treatment  (8 weeks) 
After administering the initial study dose at NIH-CC subject s continue injecting the study/comparator 
medication at home. The first  8 weeks  of injection is  considered the  Equilibration  period with  ANC 
measured  every 2 weeks (+/- 7 days)  at the subject ’s local medical facility . 
6.5.[ADDRESS_90648]’s Local Medica l Facility  Every 2 Weeks 
Subjects visit their local medical facility every 2 weeks (+/- 7 days)  for blood draws prior to the morning 
dose. 
6.5.2 Dose May be Adjusted  to Maintain ANC Between 500-1 500 cells/μL  
ANC readings are reviewed at the NIH-CC and the study drug dose may be increased for ANC < 500  
cells/ µL and decreased for ANC>1 500 cells/µL . However, any decision to adjust must take into 
consideration a subject’s  clinical course and status. D ose changes are impleme nted at the next scheduled  
shipment of study/comparator drug to the subject .  
6.6 Treatment Period (52 weeks) 
At c
ompletion of the Equilibration period, subject s commence a 52 week  treatment  period with a constant 
dose unless ANC <500  cells/µL, in which case the dose may be increased, or ANC > 7500 cells/µL absent 
concomitant infections that may elevate the ANC , in which case the dose will be decreased. Subjects visit 
NIH-CC at the start of treatment and  every 4  months  (+/- 31 days)  of treatment for a comprehensive 
assessment of chronic infections, warts and immune status. Between NIH-CC visits, subject s visit their 
local facility or provider at least once, midway between NIH-CC visits, to have blood drawn for 
CBC/ANC or  as needed for treatment of new or worsening infections. The [ADDRESS_90649]
P treatment period ends  with 
the End of Treatment (EOT) visit. 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 35 of 74 
 
 6.6.1 Assessments at  NIH -CC Every 4 Months  
Subjects visit NIH-CC every 4 months  (+/- 31 days)  after start of the T reatment  Period  for a 
comprehensive assessment of their health and safety, pregnancy status if applicable, immun ological 
markers, chronic infections, and warts.  
[IP_ADDRESS]  Labs  
• Pregnancy test for women of childbearing potential.  
• CBC with diff, Chemistries (Acute Care Panel, Creatine Kinase, Hepatic Panel, Mineral Panel, 
Total Protein, Lactate Dehydrogenase, Uric Acid), erythrocyte sedimentation rate (ESR ). 
[IP_ADDRESS]  Assessment of Overall Health and Safety  
A clinical assessment similar to what was conducted at baseline (S ection 6.2.2 ) should be repeated at each 
4-month visit to the NIH -CC.  
[IP_ADDRESS]  Measurement  of Immu nological Markers 
The following procedures are performed to assess the subject’s immunological markers:  
• Immune Status (basic): Quantitative Immunoglobulins 
• Leukocyte  Phenotypi[INVESTIGATOR_007]  
[IP_ADDRESS]  Evaluations and Consults for Assessm ent of Infections  
Subjects may  be scheduled for assessment as determined at the baseline visit or as clinically indicated by 
[CONTACT_978] [INVESTIGATOR_83103]/or warts, as described in Sections 6.3.2  and 6.3.3. 
[IP_ADDRESS]  Research  Blood  
As with the baseline assessment visits, research bloods may be collected at each visit to the NIH-CC 
including blood drawn at peak  - e.g. approximately 3 hours after the morning study drug injection.     
[IP_ADDRESS]  Quality of Life Assessment  
Subjects  will participate in quality of life surveys ( Section 7.9) with the first survey conducted early in the 
Initial Evaluation and Baseline Assessment period  and at each 4-month visit to the NIH -CC.  
[IP_ADDRESS]  Skin and Wart Biopsies (optional)  
As with the baseline assessment visits, skin and or wart biopsies may be proposed for research purposes.  
6.6.2 CBC w/diff , ESR, and Chemistries E very [ADDRESS_90650]’s Local Medical Facility  
Subjects visit their local medical facility once (at 2 months +/ - 31 days) in between their scheduled NIH-
CC visits for monitoring of their ANC and changes in blood counts (e.g. anemia or thrombocytopenia). 
Changes in kidney function and serum electrolytes ( chemistry ) and ESR (optional)  will also be requ ested 
and the results transmitted to NIH-CC. The  blood draw for the se tests should be performed prior to the 
morning dose of study drug.  
6.6.[ADDRESS_90651]’s Local Provider for New or Worsening Infections  
Subjects continue visits to  their local pro vider for routine exam s and for  treatment of new or worsening 
infections . Because the study measures the frequency and severity of infections, it is important that 
subject s submit d ocumentation of infection either through a  medica l record of their visit or through their 
provider completing  a brief  form specifying  the diagnosis, treatment, and the result of  microbial cultures 
( 40TAppendix G 40T). Subjects and their local providers are encouraged to contact [CONTACT_83169] [INVESTIGATOR_83104].  
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 36 of 74 
 
 6.6.4 End of Treatment (EOT) Visit for a Study Drug  
The last visit to the NIH-CC during the treatment period constitutes the End of  Treatment Visit (EOT) 
where a subject  ceases injection of the study or comparator drug and the subject’s response to the year’s 
treatment is assessed : 
• All assessment s to measure the study drug safety and efficacy are com pleted . 
• Subject returns all unused study drug to the NIH-CC. 
In addition  to the procedures conducted at the 4 -month visits during treatment , the following procedures 
are conducted at the EOT visit:  
• EKG,  
• Dual -energy x -ray absorptiometry (DEXA)  scan, 
• Ultrasonography of the spleen , 
• Vitamin B12 and Folate, 
• Antibody levels for Diphtheria and Tetanus . 
6.[ADDRESS_90652]’s Pre-study  Treatment 
After  completing both study treatments, subject s revert  to their pre-study treatment  regimen  and are 
offered G-CSF . Subjects continue  to submit  their diaries and  their ANC results to NIH-CC until the Study 
Completion visit. Adjustments to G-CSF dose may be made according to ANC during this phase.  Subjects of child bearing potential shall continue to maintain at least two forms of contraception.  
6.7.1 Washout Period ( 2 Days ) 
Subjects reverting back to G-CSF treatment should delay restarting G-CSF for at least two days in order 
to minimize  the possibility of drug interaction between plerixafor  and G -CSF. 
6.7.2 Monitoring the  G-CSF  Dose (1 -2 Months ) 
To accommodate potential synergistic drug interaction s between plerixafor  and G -CSF, a subject ’s initial 
G-CSF dose will be reduced and  their ANC monitored at 2-week  intervals (+/ - 7 days)  for the  first month 
and at 2-month (+/- 31 days)  intervals thereafter, or as clinically indicated.  
6.7.[ADDRESS_90653]  is unwilling or unable to continue receiving the study agent during the D ose 
Equilibration or Treatment periods, including  reasons such as 1) an i nability to maintain a minimum  ANC 
level considered safe, defined as ANC greater than or equal to 500  cells/ µL, 2) a r efusal to continue with 
the study agent , or 3) a Grade [ADDRESS_90654]  would  terminate  that phase of 
the study and proceed to the next phase.  Data handling for patients who fail to complete both arms of the 
study is detailed in the Statistics section ( Section 14). 
7 STUDY PROCEDURES AND EVALUATIONS  
7.1 Absolute Neutrophil Count (ANC)  
A primary goal in WHIMS treatment is the correction of neutropenia. The Ab solute Neutrophil Count 
(ANC) is measured  as a compon ent of a  Comple te Blood Count (CBC) test.  Normal ly between  1500-
7500 cells/µL , most WHIMS patients without G -CSF, Granulocyte Macrophage Colony -Stimulating 
Factor ( GM-CSF), or plerixafor  treatment will have a Baseline ANC between 0-500 cells/µL .   
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 37 of 74 
 
 7.1.1 Time of Day Measurement for ANC: Prior to Study  Dose  
The ANC level is measured prior to a study dose. Since p lerixafor and G -CSF are administered twice 
daily , the ANC should be measured prior to a dose to measur e the minimu m ANC level  approximately  12 
hours after a study dos e.  
7.1.2 Target ANC during 8 week  Equilibration Period  (500  – 1500 cells/µL ) 
ANC is measured approximately every 2 weeks in this 8 -week period and the dose will be adjusted for  a 
target  ANC approximately between 500-1500  cells/µ L that  we have found to be achievable with well -
tolerated low -dose plerixafor  in our preliminary studies  of patients with WHIMS .  
[IP_ADDRESS]  Subjects with a Baseline ANC > 500  cells/µL  
Subjects will be excluded if they do not have neutropenia ( Baseline ANC >1500  cells/ µL); however, if 
they do have neutropenia,  but their baseline ANC average is greater than the target ANC=500  cells/ µL, 
then they will be given the minimal dosage of both drugs specified by [CONTACT_83170] 7.1.4 ) with 
downwards adjustment possible if they exceed the maximum ANC (7500 cells/µL ). Baseline ANC is 
assessed  on at least two measurements on separate days, when a subject  is not on G -CSF, ple rixafor, or 
experiencing an acute infection.  
[IP_ADDRESS]  Subjects Unable to Attain ANC >500  cells/μL During Equilibration, Despi[INVESTIGATOR_83105] 500 cells/ µL is accepted as safe in the medical literature.  Therefore, for participants 
whose baseline ANC is <500 cells/ µL, we will  administer up to the maximal dose  for the study (0.04 
mg/kg b.i.d. for plerixafor  or 2 µg/kg b.i.d. for G-CSF), that is needed to increase the ANC to a minimum 
of 500 cells/ µL and to maintain it at this level as a minimum.  If in the dose equilibration period a study 
subject fails to attain an ANC of 500 cells/ µL on the maximum  dose cited above, they would be declared 
a failure on that treatment, stop receiving that treatment, and commence “early” crossover and washout process for switching to the [ADDRESS_90655]  
would terminate all study treatments, revert to their pre -study treatment regimen if appropriate or desired, 
and continue to the Study Completion Visit.  
7.1.3 Target ANC during the 52 week  Treatment Period  (500 – 7500 cells/µL) 
After completing the Equilibration period, subject s commence a [ADDRESS_90656]. During the treatment period, this dose will only be increased 
for ANC <500 cells/µL  or decreased for ANC  >7500 cells/ µL, in [ADDRESS_90657] been used in 
humans  for stem cell mobilization. The maximum current approved dosage  for plerixafor  = 0.24 
mg/kg/day  and this is given on up to 4 consecutive days for aphere sis ( 40TAppendix B 40T). SCN (most of 
which is due to ELANE mutations ) has been treated  with G-CSF= 2.3 to 40 µg/kg/ day ( 40TAppendix C 40T). 
The dose ranges in this study were selected based on our prior experience with the dosages that are 
effective in patients with WHIMS  in reaching the target biomarker window of 500<ANC<1500:  
G-CSF:  0.25 - 2 .0 µg/kg twice per day , 
Plerixafor :  0.01 - 0.04 mg/kg twice per day . 
The dose for plerixafor  will be reduced for renal impair ment . ( 40TAppendix E 40T)  
We already have experience treating [ADDRESS_90658] ’s baseline, 
and that the response to G-CSF once at baseline was greater than expected.(5)  Therefore, subject s 
Plerixafor  vs. G -CSF in WHIMS – Version 6.[ADDRESS_90659] ’s dose is increased  for ANC below 500 cells/µL , and maintained for ANCs up to 1500 cells/µL 
during the  8-week E quilibration period and for  ANCs up to 7500 cells/ µL during the 52-week treatment  
period. Doses of either drug  may be reduced if the steady -state counts  exceed the upper ANC threshold s 
in the absence of an acute infection . Two sequential ANC values on diff erent days prior to the morning 
study drug dose will be used at the times indicated in the protocol to make study drug dose adjustments .  
7.2.1 Initial Study/Comparator Drug  Dose s during  Equilibration P eriod  
G-CSF - without a known history of treatment with G-CSF :  0.5 µg/kg b.i.d. 
G-CSF - with a history of G -CSF dosing :   S pecified by [CONTACT_976] [INVESTIGATOR_83106].  
G-CSF - after recent treatment with plerixafor   Specified by [CONTACT_976] [INVESTIGATOR_83106] . 
Plerixafor :       0.01-0.04  mg/kg twice per day . 
7.2.2 Adjustment for ANC <50 0 cells/µL  
G-CSF:  Increas e dose to a maximum of 2.0 µg/kg b.i.d. 
Plerixafor : Increase dose to a maximum of 0.04 mg/kg b.i.d. 
7.2.3 Adjustment for ANC between 500 – 1500 cells/µL in the Equilibration Period  
G-CSF:  Maintain dose .  
Plerixafor : Maintain dose .  
7.2.4 Adjustment for ANC > 1500 cells/µL  in the Equilibration Period  
G-CSF:  The G-CSF dose may  be reduced after review of a subject’s clinical course.  
Plerixafor : The plerixafor  dose may be reduced after review of a subject’s clinical course.   
7.2.5 Adjustment for ANC > 7500 cells/µL  in the Treatment Period 
G-CSF:  G-CSF dose  may be reduced after review of a subject ’s clinical course. 
Plerixafor : The pl erixafor  dose may be reduced after review of a subject’s clinical course.  
7.3 Immune Status: Leukocyte Im munophenotypes 
Leukocyte numbers available from the CBC (ANC, etc.) will be averaged for each 1 -year treatment 
period with either the Study Drug or Comparator Drug and statistical comparison will be performed as part of the secondary endpoints.  Lymphocyte flow cytometry results (CD19+, CD4+, CD8+, etc.) will be 
averaged from the 4, 8, and 12 month visits  to the NIH-CC for each agent  and statistical comparison will 
be performed as part of the secondary endpoints . Changes in leukocyte numbers will also be analyzed by 
[CONTACT_83171].   
7.4 Medication Compliance: Study Drug and Prophylactic Antibiotics  
7.4.[ADDRESS_90660] ’s compliance with the study drug, IVIg, and  prophylactic antibiotics. 
Compliance is likely to affect  a subject ’s susceptibility to infec tion.  Considering the dura tion of study 
participation, incomplete entries can be expected ; therefore,  we encourage frequent communications with 
study subjects in an effort to collect all details concerning adverse events, infections, missed doses of study agent and other concomitant medications taken.  The references to diary card have been changed to memory aid as this is more of a tool the subjects can use in addition to information gathered by [CONTACT_83172], emails,  and phone texts,  
especially whenever a new infection, unusual side effects or a change in  medication or dose occurs.   
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 39 of 74 
 
 [IP_ADDRESS]  IVIg Treatment and Dose 
Subjects record the Date and Dose of the most recent IVIg infused.   
[IP_ADDRESS]  Record  Temperature for Fevers  
Subjects record their highest temperature for the day  if they have a fever (defined as oral temperature 
>38.[ADDRESS_90661] s are encou raged to visit their local provider if they develop a fever.  
[IP_ADDRESS]  Compliance with Prescribed Prophylactic Antibiotics  
Subjects record changes to their use of prophylactic antibiotics. 
7.[ADDRESS_90662] common side effects expected of the study drugs are listed in the Memory Aid  ( 40TAppendix F 40T) 
for subject s to rate. Subjects also have the option of  specify ing additional side effects. The rating scale 
described below is based o n CTCAE v4.0. Please note the following definitions for Activities of Daily 
Living (ADL): 
Instrumental ADL : Preparing meals, shoppi[INVESTIGATOR_007], using telephone and managing money etc.  
Self-care ADL:   Bathing, dressing, feeding, u sing toilet, taking medications and not bedridden.  
[IP_ADDRESS]  Injection Site Reaction 
Subjects inje ct the study drug subcutaneously twice per day  and record the  Injection Site R eactio n defined 
as “intense adverse reaction (usually immunologic) developi[INVESTIGATOR_58359], for the period 
between injections.   
 Not Injected:   Subject did not inject the drug.  
1 - Tenderness Tenderness with or without associated symptoms (warmth, redness, itching).  
2 - Pain   Pain; lipodystrophy;  edema (swelling); phlebitis (inflammation of  a vein ). 
3 - Ulceration  Ulceration or necrosis; severe tissue damage; operative intervention indicated. 
4 - Life-threatening  Life-threatening consequences; urgent intervention indicated.   
[IP_ADDRESS]   Bone (Skeletal) Pain: back, arms and legs  
Subjects may complain of pain  after treatment, likely due to leu kocyte mobilization. Bone pain: marked 
deep aching or throbbing discomfort in the back, arms, and legs. Subject s rate their worst pain  for the day. 
1 - Mild   Mild pain . 
2 – Moderate Moderate pain; li miting I nstrumental ADL . 
3 - Severe  Severe pain; limiting Self -care ADL . 
[IP_ADDRESS]  Other Pain: shoulder, abdominal etc. 
The study drug may cause enlargement of the spleen, which  may result in shoulder or abdominal pain. 
Subjects should record any pain not related to bone pain. 
1 - Mild   Mild pain . 
2 - Moderate Moderate pain; limiting Instrumental ADL. 
3 - Severe  Severe pain; limiting  Self-care ADL . 
[IP_ADDRESS]  Headache 
Subjects may complain of headache, a sensation of marked discomfort in various parts of the head . 
Subjects record their worst symptoms for the day.  
1 - Mild    Mild pain.  
2 - Moderate   Moderate pain; limiting Instrumental ADL. 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 40 of 74 
 
 3 – Severe  Severe pain; limiting Self -care ADL . 
[IP_ADDRESS]  Dizziness  
Subjects may complain of dizziness - disturbing sensation of lightheadedness, unsteadiness, giddiness, 
spi[INVESTIGATOR_334], or rocking. Subject s record their worst symptoms for the day.  
1 - Mild    Mild unsteadiness or sensation of movement.  
2 - Moderate   Moderate unsteadiness or sensation of movement; limiting Instrumental ADL.  
3 – Severe  Severe unsteadiness or sensation of movement; limiting Self -care ADL . 
[IP_ADDRESS]  Nausea  
Subjects may experience nausea - a queasy sensation or an urge to vomit - that may be related to the study 
drug. Subject s tabulate their symptoms for that day.  
1 – Mild   Loss of appeti te without alteration in eating habits . 
2 – Moderate   Oral intake decreased w/o significant weight loss, dehydration or malnutrition . 
3 – Severe  Inadequate oral caloric/fluid intake; tube feeding, TPN; hospi[INVESTIGATOR_374]. 
[IP_ADDRESS]  Vomiting  
Subjects ma y experience vomiting - a reflexive act of ejecting the contents of the stomach - that may be 
related to the study drug.  Subject s tabulate their  symptoms for the day.  
1 - 1 to 2 epi[INVESTIGATOR_1841]  1-2 epi[INVESTIGATOR_1841] (separated by 5 minutes) in 24 hrs.  
2 – 3 to 5 epi[INVESTIGATOR_1841]  3-5 epi[INVESTIGATOR_1841] (separated by 5 minutes) in 24 hrs.  
3 – 6 or more ≥6 epi[INVESTIGATOR_1841] (separated by 5 minutes) in 24 hrs . 
4 – Life-threatening  Life threatening consequences, urgent intervention required. 
[IP_ADDRESS]  Diarrhea  
Subjects ma y experience diarrhea – frequent and watery bowel movement - that may be related to the 
study drug. Subject s tabulate their symptoms for  the day. 
1 – Increase <4 stools Increase of 1 -4 stools per day over baseline.  
2 – Increase 4 -6 stools   Increase of 4 -6 stools per day over baseline.  
3 – Increase >=7 stools  Increase >=7 stools per day; incontinence; hospi[INVESTIGATOR_374].  
     Limiting Self -care ADL.  
4 – Life-threatening    Life threatening consequences, urgent intervention required. 
[IP_ADDRESS]  Subject Specifies Other Symptoms or Adverse Events. 
Subjects can specify other study drug reactions and rate t he severity for that day.  
 
1 – Mild   Mild sym ptoms; intervention not indicated (required).  
2 – Moderate Minimal, local or noninvasive  intervention indicated; limiting Instrumental AD L. 
3 – Severe  Medically significant but not immediately life -threatening.  
Hospi[INVESTIGATOR_374], disabling; limiting Self -care ADL.  
4 – Life-threatening  Life threatening consequences; urgent intervention required.  
7.5.2 CBC, Chemistries, ESR, and Pregnancy for Women of Childbearing Potential 
In addition to ANC  and the CBC w/diff, we may request additional  labs including  blood chemistries, and 
ESR. These standard clinical tests will allow us to monitor for changes in blood counts (anemia or 
thrombocytopenia),  changes in kidney or liver function, serum electrolytes, and blood glucose.  For 
women of childbearing potential, a urine or serum pregnancy test will be conducted.  
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 41 of 74 
 
 7.5.3 Splenic Enlargement  
There is a possibility of splenic enlargement  with both drugs : very rare cases of splenic rupture have  been 
reported in patients following the administration of G -CSF ( 40TAppendix C 40T) and rats given high doses of 
plerixafor  were found to have splenic enlargement  ( 40TAppendix B 40T). 
[IP_ADDRESS]  Spleen Ul trasonography  
Since WHIM S patients may develop splenomegaly  prior to therapy, a spl een u ltrasonography  will be 
performed prior  to the first study dose and at the end of each treatment period . Addition al sonograms may 
be performed at subsequent visits if clinically indicated.       
[IP_ADDRESS]  Spleen Assessment as part of Physical Examination at Research Assessment  
Assessment of the spleen will be part of the physical exam at NIH-CC visits every 4 months .  
7.5.4 Electrocardiogram  
An electrocardiogram (EKG) will be performed during screening to serve as baseline and to rule out preexisting cardiac arrhythmia. EKG will be repeated at the EOT visit for each treatment arm.  
7.5.5 Echocardiogram  
If an echocardiogram (ECHO) has not been performed in the previous [ADDRESS_90663] to life threatening 
arrhythmia.  
7.5.6 Dual -energy X -ray Absorptiometry (DEXA) Scans 
To monitor for the loss of bone density, dual -energy x -ray absorptiometry (DEXA) scans will be 
performed prior to the first study dose and at the end of each treatment period.   
7.[ADDRESS_90664] Memory Aid : Symptoms of Infections  
[IP_ADDRESS]  Incidence and Severity of  Fever  
Subjects should report  symptoms of  chills or fevers and take their oral temperature as required.  The 
highest tempera ture measured that day  should be recorded. Subjects are encouraged to visit their local 
provider if they develop a fever.  
[IP_ADDRESS]  Number of  Days with Fever  
Each day a subject reports an elevated oral temperature at any time during the day above 38.3°C  is 
counted as a day with fever.  
[IP_ADDRESS]   Change in Severity of Chronic Infection  
WHIM S patients often experience ongoing chronic infections with t he type, symptom, and severity 
varying amongst the patients. We plan to identify and measure changes in the severity of these infections.   
[IP_ADDRESS]  Visits to Local Provider for Medical Exam or Treatment  
Subjects should record visits at their local facility for medical exams or treatments.  
[IP_ADDRESS]  Incidence and Duration  of Antibiotic  for Treatment  
Subjects should specify any antibiotic prescribed or taken to treat an  infection and record the m edication 
activity for that day. The duration of antibiotic use is based on the number of days from the start date to 
the end date of treatment recorded in the Memory Aid . A missed day or missed partial day is included in 
the duration.  
Plerixafor  vs. G -CSF in WHIMS – Version 6.[ADDRESS_90665] s continue visits to their local medical provide r for clinical care, as per  
their routine prior to enrollment. The diagnosis and treatment results  of their infection should be 
submitted to NIH-CC using either or both of the following methods:  
[IP_ADDRESS]  Local Provider Completes a Diagnosis and Treatment Form  (option 1)  
The local provider completes the Diagnosis and Treatment form:  
• Date of Visit,  
• Chief Complaint, Onset of Symptoms , 
• Diagnosis,  New/Chronic/Recurrent/Exacerbation ,  
• Infection: Site, Type (viral, fungal, bacterial, etc..), Suspect Causative Organism,  
• Treatment Prescribed, and  
• Results of related Laboratory Tests or Cultures, 
• Outcome of Infections (Resolved, Resolved with residual Symptoms, Ongoing) , 
• Provider will be encouraged to contact [CONTACT_464]. 
Localized infection sites that are contiguous will be considered as 1 single infection. A sample form that 
can be used by [CONTACT_9137], PI, or local care provider is shown in 40TAppendix G 40T.  
[IP_ADDRESS]  Subject or Provider forwards Documents Relating to the Infection  (option 2)  
Subject obtains or requests a copy of their medical records related to the infection to be sent to NIH-CC.  
7.6.3 ENT and Audiology Evaluation at NIH -CC 
Subjects with a history of ear or sinus infections are scheduled for  Audiology and ENT  at baseline and 
completion of each  study drug treatment . Additional consults may be scheduled as medically necessary.  
7.6.4 Dental and Oral Evaluation 
Subjects are scheduled for assessment of dental caries, periodontal disease, and HPV at baseline and completion of each  study drug treatment . Additional consults  may be scheduled as medically necessary.  
7.6.5 PFT  for Subjects with Chronic Respi[INVESTIGATOR_83107] S patients frequently suffer from repeated pulmonary infections that  result in bronchiectasis and 
chronic bronchitis.  Subjects may undergo pulmonary function tests during screening and at the end of 
each treatment period. In addition, subjects with a history of respi[INVESTIGATOR_83108] a 
pulmonary consult at screening to optimize their therapy. Additional consults can be scheduled if needed for new or worsening infections/lung function  
7.[ADDRESS_90666] s with warts who consent to clinical photography, a comprehensive photo set encompassing an 
overview of the external surface of the body will be taken at baseline and at the end of each treatment period, inc luding detailed photographs of the hands and feet, which are typi[INVESTIGATOR_83109].  Detailed photos may be taken of particular warts and other types of skin infections, including infections in the anogenital areas if applicable. The photos will serve as the measure of the number and severity of infection. To ensure consistent measurements, a similar set of photos will be taken at subsequent visits to the NIH-CC. 
7.7.2 Recording the Quantity and Severity of Warts  
A case report form will be utilized to document the type, appearance, and location of the warts, 
photographs of the warts, treatments of existing warts, appearance of new warts, and representative 
warts/wart areas of interest will be quantified and tracked at each visit to the study  center . 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 43 of 74 
 
 7.7.3 Dermatolo gy Evaluation  
Subjects will be evaluated by [CONTACT_83173]. 
Additional consults may be scheduled if requested by [CONTACT_83174] . 
7.7.4 GU/GYN Evaluation   
Subjects will be scheduled for a genitourinary or gynecology exam at baseline and at the completion of 
each study drug. Additional exams can be scheduled if requested by [CONTACT_83175]/GYN or for new or worsening 
infections.  
7.8 Specimen Preparation, Handling , and Shippi[INVESTIGATOR_83110] ( HIV) and other blood-borne pathogens can occur 
through contact [CONTACT_83176], blood, and blood products, appropriate precautions will be 
employed by [CONTACT_83177][INVESTIGATOR_43558], as currently recommended by [CONTACT_83178].  
7.9 Quality of Life (SF36 v2)  
Subjects will complete a validated Quality of Life questionnaire (SF- 36, version 2) at Baseline and at the 
4, 8, [ADDRESS_90667]’s 
medical care and would otherwise be discarded, with the subject’s permission, may be requested  to be 
sent to the NIH for pathologic or research purpo ses. 
8 POTENTIAL RISKS AND BENEFITS  
8.1 Potential Risks  of plerixafor  
The dose for plerixafor  in this study is 0.01-0.04  mg/kg SQ twice per day is 3 to 12 times less than the 
FDA-approved and commonly prescribed dose of 0.24 mg/kg per day  when used in combination with G -
CSF for hematopoietic stem cell mobilization. The most common adverse reactions (ARs; ≥ 10%) 
associated with plerixafor  at 0.24 mg/kg/ day in combination with G -CSF administered subcutaneously  to 
subjects with cancer at doses that were over 3-12 fold higher than the dose that will be used in the current 
study include diarrhea, nausea, fatigue, injection site reactions, headache, arthralgia, dizziness, and vomiting.   
 
UInjection site reactions U: A temporary urticaria-like, pruritic, raised and erythematous lesion can occur at 
the injection site and is common with higher doses than will be used in this study. These reactions typi[INVESTIGATOR_83111]. Prolonged reactions if problematic will be treated with 
standard medical therapi[INVESTIGATOR_83112], oral antihistamines, etc.  
 
Musculoskeletal Pain:  Musculoskeletal pain may affect bones, muscles, ligaments, tendons, or nerves 
and may include one or a combination of the following types of pain:  Bone Pain (deep dull pain from the 
back, legs, and arms), Joint Pain or Arthralgia (pain and/or swelling in the joints), Back Pain, and or Pain 
in the Extremities .  
  
Gastrointestinal side effects: Various side effects related to gastrointestinal function have been reported 
after doses of 0.24 mg/kg including abdominal pain, diarrhea, constipation, nausea, and vomiting, all at 
Plerixafor  vs. G -CSF in WHIMS – Version 6.[ADDRESS_90668] not resul ted in the need to stop the 
medication.  
 
Excessively high white counts (leukocytosis):  Because of the mechanism of action of this medication, it is 
expected that white blood cell counts will rise. However, normal volunteers have not risen above 25,000 cells/ µL of blood after 1 day of treatment at 0.24 mg/kg/day. The subjects likely to be enrolled in this 
study generally have low circul ating WBC and are unlikely to develop leukocytosis.  As an additional 
safety measure, we are starting participants at a low dose of study medication and can lower  it if indicated 
by a high ANC count  (>7500 cells/ µL). 
 
Thrombocytopenia and bleeding: Lower platelet counts (thrombocytopenia) have been reported with 
administration of both study /comparator  drugs , but no serious bleeding events have been reported for 
plerixafor  to date.  
 
Splenic enlargement: An increase in spleen size has been shown to occur in rats treated with plerixafor  at 
proportionately higher doses than will be used here. Although this has not been reported as causing any severe problems in humans, we will monitor for clinical signs of problems by [CONTACT_83179] s about left 
shoulder or left upper quadrant abdominal pain at NIH-CC visits . If these occur, the subject will be 
evaluated by [CONTACT_83180].  
In addition, spleen size will be monitored by [CONTACT_83181] 
40TAppendix A 40T. 
 
Cardiac Arrhythmia: In one human study, 2 HIV-infected patients developed a non -life threatening 
cardiac arrhythmia consisting of frequent premature ventricul ar contractions. ( 40T10 40T) Individuals who are at 
high risk for life threatening arrhythmia based on EKG or cardiac problems detected on ECHO or who 
have a past history of life threatening cardiac arrhythmia will be excluded from this study.  
 
Paresthesia: In one  human study, some HIV-infected patients developed some transient perioral or 
peripheral numbness that resolved with discontinuation of the drug. The patients affected were treated with doses considerably higher than will be used in this study and the probl em may have been related to 
other medications, which HIV-infected patients commonly use, or HIV itself.  
 
Exacerbation of Chronic Bronchitis /Pneumonia: One of three WHIM subject s treated with plerixafor in 
our previous 6 month Phase 1 trial developed an acute exacerbation of chronic bronchitis  and a 
pneumonia during treatment .(5)  However, this is already common in untreated WHIM S patients , so 
cannot be considered a risk of plerixafor.  WHIM patients often develop bronchiectasis as they age a s a 
result of r epeated  lung infections. This may lead to poor clearance of sputum and chronic bronchitis with 
frequent exacerbations and chronic colonization of the sputum with bacterial and fungal pathogens typi[INVESTIGATOR_83113],  (i.e., Pseudomonas, Stenotrophomonas, and Aspergillus ). Increased circulating 
neutrophils from either plerixafor or G-CSF could contribute to thickened sputum, which may worsen this 
chronic problem.  If subject s have chronic respi[INVESTIGATOR_1856], sputum culture for these bacteria as well 
as tuberculosis and atypi[INVESTIGATOR_83114].  Subjects who suffer 
from this disease complication may receive pulmonary consultation and have their pulmonary treatment 
regimen optimized prior to randomization and study drug initiation. This pulmonary regimen may include drug treatments such as inhaled or nebulized beta adrenergic agonists, anticholinergic medications, hypertonic saline, prophylactic antibiotics, or DNase enzymes, and physical stimulation of the cough 
reflex with breathing devices or treatments to improve sputum clearance.  
 
Varicella Zoster Infection:  During chronic plerixafor therapy we observed reactivation of herpes zoster in 
one of three subjects. (5)  The subject  was treated with oral acyclovir and the infection resolved 
completely within days.   
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 45 of 74 
 
 8.2 Potential Risks for G -CSF 
Allergic -type Reactions:  Allergic -type reactions occurring on initial or subsequent treatment have been 
reported in <[ADDRESS_90669] two body systems‚ most often skin (rash‚ urticaria‚ facial edema)‚ respi[INVESTIGATOR_696] (wheezing‚ dyspnea)‚ and cardiovascular (hypotension‚ tachycardia). Some reactions occurred on initial exposure. Reactions tended to occur within the first [ADDRESS_90670] cases after administrati on of antihistamines‚ steroids‚ bronchodilators‚ and/or 
epi[INVESTIGATOR_238]. Symptoms recurred in more than half the subjects who were rechallenged.  
 
Splenic Rupture:  Splenic rupture, including exceedingly rare fatal cases, has been reported following the 
administration of G -CSF. Individuals receiving G -CSF who report typi[INVESTIGATOR_83115]/or 
shoulder pain will be evaluated for an enlarged spleen or splenic rupture. In addition, spleen size will be 
monitored by [CONTACT_83181] 40TAppendix A 40T. 
 
Musculoskeletal Pain:  Musculoskeletal pain may affect bones, muscles, ligaments, tendons, or nerves 
and may include one or a combination of the following types of pain:  Bone Pain (deep dull pain from the back, legs, and arms), Joint Pain or Arthralgia (pain and/or swelling in the joints), Back Pain, and or Pain in the Extremities.  
  
Acute respi[INVESTIGATOR_1505] (ARDS) : ARDS has been reported in patients receiving G-CSF, and 
is postulated to be secondary to an influx of neutrophils to sites of inflammation in the lungs. Subjects receiving G-CSF who develop fever, lung infiltrates, or respi[INVESTIGATOR_83116]. In the event that ARDS occurs, G-CSF should be withheld until resolution of ARDS 
or discontinued. Subjects will receive appropriate medical management for this condition.  
 
Alveolar Hemorrhage: alveolar hemorrhage manifesting as  pulmonary infiltrates and hemoptysis 
requiring hospi[INVESTIGATOR_83117]. Hemoptysis resolved with discontinuation of G -CSF.  
 
Growth Factor for Tumor : G-CSF is a growth factor that primarily stimulates neutrophils. However‚ the 
possibility that G -CSF can act as a growth factor for any tumor type cannot be excluded.  
 
Immunogenicity:  As with all therapeutic proteins, there is a potential for immunogenicity. The incidence 
of antibody development in subjects receiving G -CSF has not been adequately determined. While 
available data suggest that a small proportion of subjects developed binding antibodies to G -CSF, the 
nature and specificity of these antibodies has not been adequat ely studied. Cytopenias resulting from an 
antibody response to exogenous growth factors have been reported on rare occasions in subjects treated with other recombinant growth factors. There is a theoretical possibility that an antibody directed against G-CSF may cross-react with endogenous G -CSF, resulting in immune -mediated neutropenia; however, 
this has not been reported in clinical studies or in post -marketing experience. Subjects who develop 
hypersensitivity to G -CSF may have allergic or hypersensitivity reactions to other E coli-derived proteins.  
 
Cutaneous Vasculitis:  Cutaneous vasculitis has been reported in subjects treated with G-CSF. In most 
cases‚ the severity of cutaneous vasculitis was moderate or severe. Most of the reports involved subjects with severe chronic neutropenia receiving long-term G -CSF therapy. Symptoms of vasculitis generally 
developed simultaneously with an increase in the ANC and abated when the ANC decreased. Many subjects were able to continue G-CSF at a reduced dose.  
 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 46 of 74 
 
 Aortitis - inflammation of the aorta:   Aortitis  has been reported in patients who received G-CSF . 
Symptoms may include fever, abdominal pain, feeling tired, and back pain.   
The following AEs have been identified during post -approval monitoring of G-CSF: splenom egaly, 
splenic rupture, ARDS, alveolar hemorrhage and hemoptysis, sickle cell crisis, cutaneous vasculitis, aortitis, Sweet’s syndrome (acute febrile neutrophilic dermatosis), decreased bone density and 
osteo porosis in pediatric  severe chronic neutropenia subjects receiving chronic treatment with G-CSF.  
8.3 Risks and Discomforts of Phlebotomy
 
53TSubjects will undergo repeat blood sampling on several occasions during the initial phase of the study 
and during the treatment period. For research blood purposes, each venipuncture will be for 3 mL to 120 
mL of blood in adul ts. 53TPhlebotomy for blood tests may cause pain , lightheadedness/fainting, or lead to 
the formation of a small subcutaneous hematoma caused by [CONTACT_83182] a punctured blood vessel. The hematoma causes only minor discomfort ; it is not dangerous and requires no treatment other than 
reassurance to the subject. There is also a small risk of infection at the site of the needle puncture, which can be readily treated with antibiotic therapy. At the time of enrollment, each subject will be asked about 
their participation in other research studies to ensure that the amount of blood drawn does not exceed the limits allowed for ad ult subjects by [CONTACT_4517] (Medical Administrative Series Policy #:  
M95-9: Guidelines for Limits of Blood Drawn for Research Purposes in the Clinical Center. Available at:  
http://cc -internal.cc.nih.gov/policies/PDF/M95 -9.pdf  
8.[ADDRESS_90671]  (i.e., risk of cancer 
development is increased with “high risk” HPV types).  
8.[ADDRESS_90672] the option of having bone marrow biopsy done for research purposes, which  could be 
performed as an outpatient procedure . Local anesthetics will  be used to prepare the biopsy site and IV 
conscious sedation may be offered to subjects for comfort; these agents may resul t in transient local 
discomfort initially and occasionally be associated with allergic reactions. General anesthesia will only be given if the participant is admitted for the procedure.  The primary risks of bone marrow biopsy include 
local pain, bleeding, and infection. Antibiotics and oral analgesics will be used to manage pain and 
infection.  
8.[ADDRESS_90673] s will be closely monitored at the NIH-CC as outpatients 
during this per iod.   
8.7 Potential Benefit 
G-CSF is an  FDA-approved treatment for neutropenia and has been shown to reduce infection in 
congenital neutropenia .(
40T24 40T) ( 40TAppendix C 40T) Plerixafor  is a specific antagonist of CXCR4 and provides a 
novel molec ularly targeted potential therapy for WHIMS. Recent Phase I dose-escalation studies of 
Plerixafor  vs. G -CSF in WHIMS – Version 6.[ADDRESS_90674] s demonstrated  that the drug mobilizes not only neutrophils but also all 
other  leukocyte subsets that are decreased in the blood of WHIMS patients.( 40T3, 4 40T) Furthermore, low -dose 
therapy with plerixafor  alone for 6 months in 3 subjects resulted in a reduction of infections , no new warts 
and possible improvement of existing warts, and no safety concerns.(5) This collective experience 
appeared to be an improvement compared to pre and post study treatments of the same subjects with G -
CSF. 
8.7.1 Reduced Infections  
G-CSF has been shown to be effective in alleviating neutropenia and reducing infection in patients with 
chronic neutropenia ( 40T24 40T) and there is some limited anecdotal and retrospectively controlled evidence that 
plerixafor  may also have clinical benefits.  The aim of this study is to define which drug is superior in 
WHIMS patients. Th e crossover design ensures that all subject s are able to receive both treatments: 
subject s without prior treatment with either agent may  experi ence improved outcomes from either 
treatment, while subject s previously on G -CSF may obtain benefits with plerixafor . 
8.7.[ADDRESS_90675] identified low 
dose rang es able to maintain the ANC within the target range for the present study of 500-1500 
cells/microliter, which is considered in the literature as ‘safe’ .  At these doses, we have observed no 
toxicity attributed to either plerixafor  or G-CSF and both appear to be well-tolerated.   
8.7.3 Control of Warts  
Limited evidence suggests that during chronic treatment with plerixafor in WHIMS patients , warts are 
improved in appearance and size and seem not to recur which is different from the patient’s prior 
experience on/off G -CSF therapy.  This may indicate a beneficial effect of plerixafor  treatment in HPV 
disease. (5)  This study is designed to further investigate and validate this preliminary result . 
8.7.4 Increased Leu kocyte Response 
Preliminary published evidence sugge sts that plerixafor  is capable of increasing all leukocytes measured 
that are diminished in the circulation of WHIM S patients (neutrophils, CD4+/CD8+ lymphocytes, B cells, 
and monocytes) in contrast to G -CSF, which increased mainly  neutrophils. (3-5)  It is currently unknown 
whether the increased circulating leukocytes convey the expected benefits in terms of reducing infection 
or improving the immune system function and this study is designed to further investigate and validate 
this. 
[ADDRESS_90676] access to the samples and data. Samples and data acquired will be tracked using software designed for this purpose.  
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 48 of 74 
 
 9.3 Sharing of Samples and Data  
Other investigators at the NIH or ou tside  may wish to study these samples and/or data. In that case, IRB 
approval must be sought prior to any sharing of samples and/or data. Any clinical information shared about the sample wo uld similarly require prior IRB approval . 
9.4 Reporting Loss or Unanticipated Destruction of Samples  
Any loss or unanticipated destruction of samples or data (for example, due to freezer malfunction) that is 
a Serious Protocol Deviation or compromises the scientific integrity of the data collected for the study, 
will be repor ted to the National Institute of Allergy and Infectious Diseases (NIAID) IRB. 
9.[ADDRESS_90677]’s participation in other protocols at NIH.  
9.5.2 At Completion of Study  
At the completio n of the protocol (termination), samples will either be destroyed, or after IRB approval, 
transferred to another existing protocol . 
10 REMUNERATION PLAN FO R SUBJECTS  
Study subjects and their families will not receive any per visit reimbursement  for the clinical trial. 
However for optional procedures performed for research purposes only, $120.00 will be paid for each wart and/or skin biopsy, and $[ADDRESS_90678], information regarding AEs will be elicited by [CONTACT_83183]:  
• Immediately documented in the subject’s medical record/source document. 
• Recorded in Clinical Research In formation Mana gement System , and  
• Reporte d as outlined below (e.g., IND s ponsor, IRB, FDA). 
11.2 Definitions  
Adverse Event (AE)  
An AE is any untoward or unfavorable medical occurrence in a human subject, including any abnormal 
sign (e.g., abnormal physical exam or laboratory finding) , symptom , or disease, temporally associated 
with the subject’s participating in the research, whether or not considered related to the research.  
 Adverse Reaction (AR) or Adverse Drug Reaction (ADR)   
An AE  that is caused by [CONTACT_4523] (drug or biologic).  
 Suspected Adverse Reaction (SAR)  
An AE  for which there is a reasonable possibility that the investigational agent caused the AE . 
‘Reasonable possibility’ means that there is evidence to suggest a causal relationship between the drug and the AE. A SAR  implies a lesser degree of certainty about the causality than an AR,  which implies a 
high degree of certainty.  
 Serious Adverse Event (SAE) 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 49 of 74 
 
 A serious AE  (SAE ) is an AE  or any untoward medical occurrence  that at any time results in 1 or more of 
the following outcomes:  
• Death  
• Life threatening event (immediate threat to life)  event   
• An inpatient hospi[INVESTIGATOR_1324],  
• A persistent or significant incapacity or substanti al disruption of the ability to conduct normal life 
functions,  
• A con genital anomaly or birth defect , 
• A medically important event *  
 *Medical and scientific judgment sho uld be exercised in deciding whether other situations should be 
considered serious, such as important medical events that may not be immediately life threatening or resul t in death or hospi[INVESTIGATOR_059] , but they may jeopardize the subject or may require intervention to 
prevent 1 of the other outcomes listed above.  
 
Unexpected Adverse Event   
An AE is unexpected if it is not listed in the Investigator’s Brochure or Package Insert (for marketed 
products) or is not listed at the specificity or severity that has been observed.  It is the responsibility of the IND Sponsor to make this determination.  
 
Serious and Unexpected Suspected  Adverse Reaction (S[LOCATION_003]R)  
A S[LOCATION_003]R is a Suspected Adverse Reaction that is both Serious and Unexpected.   
 
Unanticipated Problem  (UP)   
An UP is any event, incident, experience, or outcome that is  
1. Unexpected in terms of nature, severity, or frequency in relation to: 
• The research risks that are described in the IRB -approved research protocol and informed consent 
document, investigator’s b rochure , or other study documents; and 
• The characteristics of the subject pop ulation being studied; and  
2. Possibly, probably, or definitely related to participation in the research; and 
3. Places subjects or others at a greater risk of harm (including physical, psychological, economic, or 
social harm) than was p reviously known or recognized. Per the IND sponsor, an AE with a serious 
outcome will be considered increased risk.  
 Unanticipated Problem That I s Not an Adverse Event (UPnonAE)  
Unanticipated problem that is not an Adverse Event (UPnonAE): An unanticipated problem that does not fit the definition of an adverse event, but which may, in the opi[INVESTIGATOR_871], involve risk to the 
subject, affect others in the research study, or significantly impact the integrity of research data.  Such 
events would be considered a non-serious UP. For example, we will report occurrences of breaches of confidentiality, accidental destruction of study records, or unaccounted -for study drug.  
 Protocol Deviation  
Any change, divergence, or departure from the IRB approved study procedures in a research protocol. Protocol deviations are designated a s serious or non -serious and further characterized as  
 1. Those that occur because a member of the research team deviates from the protocol. 
2. Those that are identified before they occur, but cannot be prevented.  
3. Those that are discovered after they occur  
 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 50 of 74 
 
 Serious Protocol Deviation: A deviation that meets the definition of a Serious Adverse Event or 
compromises the safety, welfare or rights of subjects or others.  
 
Non –compliance :  The failure to comply with applicable NIH HRPP policies, IRB requirem ents, or 
regulatory requirements for the protection of human subjects. Non-compliance is further characterized as  
1. Serious: Non -compliance that  
a. Increases risks, or causes harm, to participants 
b. Decreases potential benefits to participants 
c. Compromises the integrity of the NIH-HRPP 
d. Invalidates the study data 
2. Continuing: Non-compliance that is recurring  
3. Minor: Non-compliance that, is neither serious nor continuing.  
11.3 Investigator Assessment of Adverse Events 
If a diagnosis is clinically evident (or subsequently determined), the diagnosis rather than the individual 
signs and symptoms or lab abnormalities will be recorded as the AE.  All AEs occurring after enrollment  
through the final study visit will be documented and recorded , and those not related to disease progression 
will be reported as described below in Section 11.4 and Section 11.5 .   
 A laboratory abnormality should be reported as an AE if it requires an intervention. Interventions include, but are not limited to, discontinuation of treatment, dose reduction/delay, additional assessments, or concomitant treatment. In addition, any medically important laboratory abnormality may be reported as an AE at the discretion of the investigator. This could include a laboratory result for which there is no intervention but the abnormal value suggests disease or organ toxicity.  
 The i nvestigator will ev aluate all AEs with respect to the seriou sness (criteria listed above), severity 
(intensity or grade), and c ausality (relationship to the study agent and relationship to research) according 
to the following guidelines.  
11.3.1  Severity  
The investigator will grade the severity of each AE according t o the “Common Terminology Criteria for 
Adverse Events (CTCAE)” (v 4.0):  
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm  
 
Severity grading for clinical events not found in the toxicity table will be graded according to the  
following grading scale:  
1. Grade 1 (Mild):  Events causing no or minimal interference with usual social and functional 
activities . 
2. Grade 2 (Moderate ): Events causing greater than minimal interference with usual social and 
functional activities . 
3. Grade 3 (Severe) : Events causing inability to perform usual social and functional activities . 
4. Grade 4 (Potentially Life -Threatening) : P 
PEvents causing inability to perfor m basic self -care 
functions OR medical or operative intervention is indicated to prevent permanent imp airment, 
persistent disability, or death .  Note:  A  severity assessment of “potentially life -threatening” event 
is not necessarily the same as a life -threatening event, when used as an "SAE" criterion. The latter 
means that the event is an immediate threat to life as opposed to a potential threat to life.  
5. Grade 5 (Death) .  
11.3.2  Causality    
Causality (likelihood that the event is/is not related to th e study agent)  will be assessed considering the 
factors listed under the following categories:  
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 51 of 74 
 
 Definitely Related   
• Reasonable temporal relationship . 
• Follows a known response pattern . 
• Clear evidence to suggest a causal relationship . 
• There is no alternative etiology . 
 
Probably Related 
• Reasonable temporal relationship . 
• Follows a suspected response pattern (based on similar agents). 
• No evidence of a more likely alternative etiology . 
 Possibly Related  
• Reasonable temporal relationship . 
• Little evidence for a more likely alternative etiology . 
 Unlikely Related  
• Does not have a reasonable temporal relationship .  
OR 
• Good evidence for a more likely alternative etiology . 
 
Not Related  
• Does n ot have a temporal relationship.          
OR 
• Definitely due to an alternative etiology . 
 
Note: Other factors (e.g., dechallenge, rechallenge) sho uld also be considered for each causality category , 
when appropriate. Causality assessment is based on available information at the time of the assessment of  
the AE. The investigator may revise the causality assessment as additional information becomes 
available. 
11.4 Investigator Reporting Responsibilities to the Sponsor  
11.4.1  Adverse Events 
Line listings, frequency tables, and other summary AE data will be submitted to the IND sponsor when 
needed for periodic safety reviews, review of IND annual reports, review of IND safety reports, and 
preparation of final study reports.  
11.4.2  Serious Adverse Events  
All SAEs (regardless of relationship and whether or not they are also UPs)  must be reported on the Safety 
Expedited Report Form (SERF) and sent to  the Sponsor Clinical Safety Office (CSO) by [CONTACT_3719] e- mail 
attachment. Deaths and immediately life threatening SAEs must be reported to the CSO within [ADDRESS_90679] INFORMATION:  
OCRPRO Clinical Safety Office  
[ADDRESS_90680]  
Frederick, MD [ZIP_CODE]  
Phone : [PHONE_070]  
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 52 of 74 
 
 Fax: [PHONE_016]  
E-mail: [EMAIL_007]   
11.4.[ADDRESS_90681] be reported to the CSO and sent by [CONTACT_3719] e-
mail attachment no later than 7 calendar days of site awareness of the event. UPs that are not AEs are not reported to the Sponsor CSO.  
Report all UPs that are also adverse events to the CSO on the NIH Problem Report Form.  
11.4.4  Protocol -Specified Events  
There are no protocol -specified events.  
11.4.5  Pregnancy  
Pregnancy itself is not an AE. However, complications from pregnancy are AEs and may be SAEs. Pertinent obstetrical information for all pregnancies will be reported to the CSO via fax or e- mail within 3 
business days from the site’s awareness of the pregnancy.   
 
Pregnancy outcome data (e.g., delivery outcome, spontaneous, or elective termination of the pregnancy) will be reported to the CSO within 5 business days of the site’s awareness of the outcom e on a protocol -
specified form. In the event of pregnancy, the subject will be followed to term for safety monitoring.  In 
the event of pregnancy : 
• Treatment for  the subject  will be un -blinded;  
• If subject  is being treated with plerixafor , the study drug will be discontinued; 
• If subject  is being treated with G-CSF, the study comparator drug may be withheld for  the [ADDRESS_90682]
P 
trimester;  
• Subject will be advised to notify their obstetrician;  
• Pregnancy will be reported to the Data Safety Monitoring Board (DSMB).  
11.5 Investigator Reporting Responsibilities to the NIAI D IRB  
11.5.1  Expedited Reporting  
Serious and non-serious Unanticipated Problems, deaths, serious deviations, and serious or continuing non-compliance will be reported within 7 calendar days of investigator awareness. Serious Adverse Events that are possibly, probably, or definitely related to the research will be reported to the NIAID IRB within 7 calendar days of investigator’s awareness, regardless of expectedness.  
11.5.[ADDRESS_90683] of the protocol will not be reported to the IRB unless they occur at a rate greater than anticipated by [CONTACT_3476]. Expected adverse events will not be reported to the IRB unless they occur at a rate greater than that known to occur in WHIMS . If the rate of these events exceeds 
the rate expected by [CONTACT_3476], the events will be classified and report ed as though they are 
unanticipated problems. Deaths related to the natural history of WHIMS  will be reported at the time of 
continuing review.  
11.5.3  Annual Reports   
The following items will be reported to the NIAID IRB in summary at the time of continuing revi ew: 
• Serious and non-serious unanticipated problems  
• Expected SAEs that are possibly, probably, or def initely related to the research; 
• SAEs that are not related to the research;   
• All adverse events, except expected AEs and deaths granted a waiver of reporting.  
• Serious and Non-Serious Protocol deviations  
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 53 of 74 
 
 • Serious, continuing, and minor non-compliance 
• Any trends or events that in the opi[INVESTIGATOR_52567].  
11.[ADDRESS_90684] (by [CONTACT_79844]) are followed until 
the final outcome is known or until the end of the study. AEs that have not resolved by [CONTACT_83184] “ongoing” , and will be  followed until the final outcome is known. If it is not 
possible to obtain a final outcome for an SAE , the investigator will record the reason a final outcome 
could not be obtained. SAEs that occur after the end of the study that are reported to and are assessed by 
[CONTACT_1010], probably, or definitely related must be reported to the CSO, as described 
above.  
11.7 Investigator Initiated Trial (IIT) Sponsor  Obligations a nd Reporting Responsibilities  
Serious and unexpected suspected adverse reactions as defined in FDA 21 Code of Federal Regulations 
(CFR) 312.32 and determined by [CONTACT_83185]. The 
IND sponsor will also su bmit an IND Annual Report of the progress of the investigation to the FDA, as 
defined in 21 CFR 312.33.  AEs that are also UPs will be summarized by [CONTACT_83186] . 
 For this Investigator Initiated Trial (II T): 
• The IIT  sponsor (OCRPRO) warrants that the study will be performed in compliance with all 
applicable local and international laws and regulations, including without limitation ICH E6 
guidelines for Good Clinical Practices.  
• The IIT sponsor shall be responsible for the respect of all obligations required by [CONTACT_83187].  
• The sponsor shall be responsible for ensuring submission of required expedited and periodic reports to the FDA and the NIAID IRB.  The IIT sponsor is responsi ble for providing any “Dear 
Investigator Letter” (DIL) for new safety finding received from [COMPANY_011] group entity to the investigators and Ethics Committee .  
• The sponsor must report the following information in English to the [COMPANY_011] group entity Pharmacovigi lance contact:  
1. Routine transmission of: All Serious Adverse Events (SAEs). These events must be transmitted within 1 working day of the sponsor ’s awareness or identification of the event.  
     Results of any relevant complementary exams performed to obtain the final diagnosis of any 
SAE (e.g., hospi[INVESTIGATOR_44458], autopsy, consultation) will be made available to [COMPANY_011] group entity upon request.  
2. Other events or periodic reports (e.g. Development Safety Update Report (DSUR)), submitted to the  FDA must be transmitted at the time of submission.  
3. Other significant safety issues or findings in a study pertaining to safety of product must be 
transmitted within [ADDRESS_90685]  
 
Fax/email of SAE Reports to  [COMPANY_011]: 
Plerixafor  vs. G -CSF in WHIMS – Version 6.[ADDRESS_90686]/ISS Investigators will notify [COMPANY_011]  via fax or email, attention [COMPANY_011]  Pharmacovigilance (PV):  
  
Fax:  908 -203-7783 (US)    
E-mail :[EMAIL_1656]  
11.[ADDRESS_90687] ered to subjects and 
suspension of enrollment in this study until a decision is made whether or not to contin ue the study agent 
administration.  
 
The halting criteria  include:  
1. Two or more subjects experience the same or similar SAEs that are unexpected and are possibly, 
probably, or definitely related to the study agent , or 
2. Any safety issue that the site investigators determine sho uld halt the study .  
 The IRB,  IND sponsor, or the FDA may halt the study at any time following review of any safety 
concerns. The DSMB may recommend a study halt.  
11.8.1  Reporting of Study Halting  
If a halting requirement is met, a description of the event(s) or safety issue must be reported by [CONTACT_978] 
[INVESTIGATOR_874] [ADDRESS_90688] in this study include:  
1. A subject experiences an SAE or a  grade 3 or greater AE that is unexpected  (as determined by [CONTACT_70736])  and is possibly, probably, or definitely related to the study agent; or 
2. Development of any exclusion criteria may be cause for discontinuation; or 
3. Any safety issue that the investigator determines should pause administration of the study agent to a single subject . The IND sponsor, in collaboration with the PI, may also pause for an individual subject 
if a safety concern is identified during routine aggregate data analysis. 
11.9.[ADDRESS_90689]/group. The IND sponsor will notify the si te investigators 
of this decision. The site investigators will notify their local IRB(s) of the decision to resume administration of the study agents prior to resumption.   
Plerixafor  vs. G -CSF in WHIMS – Version 6.[ADDRESS_90690] will be withdra wn from the study for any of the following:  
1. A subject’s decision (investigator shoul d attempt to determine the rea son for the subject’s 
decision).  
2. Any clinical AE, laboratory abnormality , or other medical condition or situation such that 
continued participation in the study woul d not be in the best interest of the subject.   Subjects will 
be followed for the duration of the study for indicated safety assessments.  
3. Non-compliance with study procedures to the extent that it is potentially harmf ul to the subject or 
to the integrity of the study data.  
4. A change in the subject’s baseline condition after enrollment so that the subject no longer meets the inclusion/exclusion criteria.   
11.11 Additional Enrollment for Withdrawn Subjects  
Subjects who are not evaluable as described in the Statistics ( Section 14) may be replaced with other 
eligible subjects . 
12 SAFETY OVERSIGHT AND MONITORING PLAN  
12.1 Safety Review and Communication Plan 
A Safety Review and Communication Plan (SRCP) has been developed for the protocol. The SRCP is an 
internal communications document between the PI [INVESTIGATOR_83118], which delineates the safety 
oversight responsibilities of the PI, the CSO, and other stakeholders. The SRCP also includes the overall 
plan for conducting periodic safety surveillance assessments. 
12.2 Sponsor Medical Monitor  
A sponsor medical monitor  representing the IND sponso r (OCRPRO ), has been appointed for the safety 
oversight in this clinical study. The sponsor medical monitor will be responsible for performing safety 
assessments as outlined in a Safety Review and Communications Plan.  
12.[ADDRESS_90691] be satisfied that the 
timeliness, completeness, and accuracy of the data submitted to them for review are sufficient for evaluation of the safety and welfare of the study subjects. The DSMB may also convene as needed, if stoppi[INVESTIGATOR_23893], or other safety issues arise that the PI [INVESTIGATOR_1238]/or NIAID clinical director or designee 
would like the DSMB to address.  The PI [INVESTIGATOR_83119]. The PI [INVESTIGATOR_83120] a recommendation concerning continuation, modification, or termination of the study. The PI  [INVESTIGATOR_83121].  
12.[ADDRESS_90692]  and their local physician will be told of their status.  
Whenever possible the PI [INVESTIGATOR_83122].  If this is unavoidable, the IRB, DSMB, and CSO will be notified. 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 56 of 74 
 
 13 CLINICAL MONITORING STRUCTURE  
13.1 Site Monitoring Plan  
As per International Conference on Harmonization (ICH) Good Clinical Practice (GCP) 5.18, clinical protocols are required to be adequately monitored by [CONTACT_4530]. This study monitoring will be conducted according to the NIAID Intramural Clinical Monitoring Guidelines. Monitors under contract to the NIAID/ OCRPRO will visit the clinical research site to monitor all aspects of the study in accordance 
with appropriate reg ulations and the approved protocol. The objectives of a monitoring visit will be: 1) to 
verify the existence of signed informed consent documents for each monitored subject; 2) to verify the prompt and accurate recording of all monitored data points and prompt reporting of all SAEs; 3) to compare abstracted information with individual subjects’ records and source documents (subjects’ charts, laboratory analyses and test resul ts, physicians’ progress notes, nurses’ notes, and any other relevant 
original subject information); and 4) to ensure the investigators compliance with the protocol,  and 
completeness and accuracy of the study records. The monitors also will inspect the clinical site reg ulatory 
files to ensure that reg ulatory requirements (Office for Human Research Protections [OHRP]) and 
applicable guidelines (ICH -GCP) are being follo wed. During the monitoring visits, the investigator 
(and/or designee) and other study personnel will be available to discuss the study progress and monitoring visit. 
  
The investigator (and/or designee) will make study documents (e.g., consent forms, and pertinent hospi[INVESTIGATOR_893]) readily available for inspection by [CONTACT_1036], site monitors, and NIAID staff for confirmation of the study data. A specific protocol -monitoring plan will be discussed with the PI [INVESTIGATOR_83123]. The plan will outline the frequency of monitoring visits based on factors such as study enrollment, data collection status, and reg ulatory obligations.  
 A monitoring visit will occur after the first five participants have been treated for 6 months in o rder to 
ensure completeness of reports sent by [CONTACT_83188]. 
14  STATISTICAL CONSIDER ATIONS  
14.1 Study Hypotheses  
The primary hypothesis is that the Total Infection Severity Score (TISS) will be significantly reduced  
while on plerixafor compared to GCSF. The TISS score is the sum of the Infection Severity Scores (
40TAppendix D 40T) for all infections during each period (1 year of treatment). Secondary endpoints include 
infection related parameters, wart response, immunological parameters, and measures of chronic 
infections, side effects, quality of life, and treatment preference.  
14.[ADDRESS_90693] ion of 50% between the TISS score during the plerixafor period and the TISS score 
during the G -CSF period. Table [ADDRESS_90694] using an 
alpha = 0.[ADDRESS_90695] and setting power at 90%.  The groups are d efined by [CONTACT_83189] (meaning G- CSF first then plerixafor)  or pG (for plerixafor treatment  first, followed by G -
GSF).    
Table 1 :  Sample size required to achieve 90% power under different assumptions for the mean 
response on G -CSF and plerixafor.  Power formula based on a two -sided two sample t -test with 
alpha=0.[ADDRESS_90696] deviation of 10 for the difference is assumed.  
Plerixafor  vs. G -CSF in WHIMS – Version 6.[ADDRESS_90697]
e Size  
21 10 52.4%  11 -11 22 12 
21 11 47.6%  10 -10 20 14 
21 12 42.9%  9 -9 18 16 
21 13 38.1%  8 -8 16 20 
21 14 33.3%  [ADDRESS_90698] 38% -43% reductions in TISS while on 
plerixafor.   Such reductions would be clinically meaningful and we will thus aim to enroll [ADDRESS_90699] to provide robustness to the possibility of secular trends in the TISS score over the two 
periods.   
14.3 Study Population  
Our study population will be genetically proven WHIM patients (known compatible heterozygous CXCR4 mutation) age 10- [ADDRESS_90700] a history of recurrent infections and are neutropenic (ANC<1500 
at baseline).  These individuals would be likely to benefit from either the study drug or the comparator agent.  Subjects will be recruited for participation among those being followed at NIH ( 24 as of May 
2014), followed elsewhere in the US or other countries, newly diagnosed by [CONTACT_83190], immunologists, gynecologists, urologists, or primary care physicians or self -referred.   
As with U S subjects , subjects recruited from other countries will receive their routine care and obtain 
blood counts from their local providers and visit the NIH -CC per study schedule. 
14.4 Description of Analysis  
14.4.1  Efficacy Analysis – Infection Severity Score (ISS)  
Data from a subject ’s study Memory Aid  such as visits to a subject ’s local medical provider, anti -
infective prescriptions, fevers (oral temperature >38.3
Po
PC), h ospi[INVESTIGATOR_059], and diagnoses of infection 
from the subject ’s medical provider, are collected, reviewed and scored at the study center  by [CONTACT_941] P I 
according to specific pre-defined weighting rules ( 40TAppendix D 40T) designated the ISS. 
[IP_ADDRESS]   Infection -related Events  
An Infection -related Event is defined by [CONTACT_39132]:  
1) Diagnosis of Infection by a Clinician : Subject s are encouraged to visit their local medical 
provider if they experience symptoms of a new or worsening infection such as fevers, chills, aches, pain, worsened cough, swelling, redness, etc. Subjects record visits to their local medical 
provider in their Memory Aid  and provide documentation of the diagnosis and treatment to the 
NIH-CC. If a provider clinically diagnoses an infection (i.e. otitis, sinusitis, dental infection, bronchitis, pneumonia, ab scess), th is is recorded and counted as an Infection-related Event.  
2) Presumed Diagnosis of Infection by a Clinician: The precise cause of an infection cannot always 
be determined. A differential diagnosis of possible infections and/or biomarker indications  of an 
infection will be counted as an infection.  
3) Resolution of Infection Symptoms after Treatment with Antibiotics : Subjects with chronic or 
recurrent infections may have a standing prescription for antibiotics without need to visit their 
local medical providers prior to initiating treatment. Because subjects record their symptoms of 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 58 of 74 
 
 infection and any antibiotic taken for treatment in their Memory Aid  ( 40TAppendix F 40T), resolution of 
likely symptoms of infection (for example fever, pain, or worsened cough) coincident with commencing an  antibiotic regimen  will be counted as an Infection -related Event  even if not 
diagnosed clinically.  
[IP_ADDRESS]  Severity of Fever for an Infection -related Event  
The highest temperature recorded during an epi[INVESTIGATOR_83124] D . 
Fevers that are of indeterminate origin (i.e. not clearly associated with an Infection) are counted as a fever, but are not included in the ISS.  
[IP_ADDRESS]  Level of Antibiotic Treatment for an Infection-rela ted Event  
The highest level of prescribed antibiotic treatment (topi[INVESTIGATOR_2855], oral, or parenteral) for an Infection is scored 
and described in the Infection Severity Score in 
40TAppendix D 40T.  
[IP_ADDRESS]  Extent of Hospi[INVESTIGATOR_83079]-r elated Event 
The highest level of care i s scored as described in the Infection Severity Score in Appendix D .  
14.4.[ADDRESS_90701] under a ranking scheme 
where we form a score for each person  
  
S = (TISS during period 1 – TISS during period 2),  
 
where TISS is the Total Infection Severity Score , which is the sum of all ISSs during a period. For 
example, if a subject  had 3 infections on plerixafor with ISSs of 4, 1, 3 and 2 infections on GCSF with 
ISSs of 5,1, the score would be (4+1+3) – (5+1) = 8 -6=2.    
 
It is possible that not all subject s will have complete follow-up for both periods.  We next describe how to 
handle such subjects. Drug failures are subjects who must discontinue their assigned drug because 1) drug 
is intolerable and the subject  refuses to take the study drug , 2) the ANC is reliably less than 500 cells/µL 
or 3) an adverse event preclud es further study drug administration.  Drug fa ilures in tr eatment period 1 
cross over to the opposite arm ; drug failures in treatment period [ADDRESS_90702] rank. Let S* be the largest of the absolute value of the scores for all subjects 
with complete data.  To operationalize giving the worst rank, we will give drug failure s during the first 
period a score of S*+1. If a drug failure occurs during the second period, they receive a score of -(S*+1).  
Subjects who are drug failures in each period receive a score of 0.    
 Apart from drug failures, some subject s may drop out of the study for reasons different than the above 
three. F or subject s who drop out in period [ADDRESS_90703] 3 months of follow-up  an adjus ted score will be 
formed. 
S = TISS in period 1 -  (TISS in period 2)/f  
 
where f is the fraction of intended follow -up attained in period 2 (note that f>=3/12). Based on these 
scores, we will calculate a permutation p -value using the  two-sample Wilcoxon rank test. Subjects who 
drop out in period [ADDRESS_90704] s or developi[INVESTIGATOR_007] a model to help allow imputation of missing data, 
or performing a model based analysis.  
 All tests will be two-sided with a type I error rate of 0.05.  
Plerixafor  vs. G -CSF in WHIMS – Version 6.[ADDRESS_90705]  has data for the primary analysis if  
1) They have completed 1 year of plerixafor treatment and 1 year of G -CSF treatment  
2) Are a drug failure on either plerixafor or G -CSF (or both) 
3) They drop out in period 2 after 3 months of follow -up. 
 No interim analysis for efficacy is planned; it is difficult for a rank -based procedure to achieve a small p -
value after [ADDRESS_90706] been enrolled  
after 2 years (counting time from the first enrollment), or if it is clear earlier that fewer than [ADDRESS_90707] data for the primary 
analysis.     
14.4.5  Safety Analy sis 
The following tables of AEs will be completed  after unblinding the study : 
• A listing of all SAEs including the treatment arm to which the subject was assigned.  
• Frequency tables of AEs by [CONTACT_2939], severity, and reported relationship to treatment.  
14.4.6  Secondary Analysis  
[IP_ADDRESS]  Secondary endpoints  
 Secondary endpoints (incidence of fevers and number of febrile days, incidence of hospi[INVESTIGATOR_83125], incidence of antibiotic treatment and number of antibiotic days, number of 
infections an d number of days with infections, number of new visible warts, and the change in severity 
for existing warts) will follow the same type of analysis as described above with the TISS being replaced by [CONTACT_83191], number of febrile days, etc. All tests will be two -sided with a type I error rate of 
0.05.  
[IP_ADDRESS]  Incidence and Duration of Infection -related Event  
An infection -related Event will be counted as an incidence of infection . The duration of infection is the 
number of days the symptoms of infection are pr esent.  
[IP_ADDRESS]  Incidence and Duration of Fever  
Febrile d ays are defined as day s in which the subject’s oral temperature  ≥ 38.3°C, at any point during the 
day (or 24 hour period). Contiguous days of f ever will be counted as an incidence of fever . For 
subsequent fevers to be considered a new/additional incidence of fever, an interval of at least [ADDRESS_90708] separate each event of a fever.   
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 60 of 74 
 
 [IP_ADDRESS]  Incidence and Duration of Antibiotic  Treatment  
A prescribed treatment with a new antibiotic (oral, IV, or topi[INVESTIGATOR_2855]) is counted as an incidence of antibiotic 
treatment.  The duration of antibiotic treatment is the number of days a subject is under treatment with an 
antibiotic other than a prop hylactic antibiotic; missing an occasional dose does not invalidate the count 
for that day. For example if a subject  is asked to take a [ADDRESS_90709]  actually 
takes all 10 days or misses a day.  Additional antibiotic treatments during or after the initial treatment are counted as additional incidences of antibiotic treatment. 
[IP_ADDRESS]  Incidence and Duration of Hospi[INVESTIGATOR_83126] a hospi[INVESTIGATOR_83127] . Hospi[INVESTIGATOR_83128] a subject  is in a hospi[INVESTIGATOR_83129] a 
diagnosis (or presumed diagnosis) of infection. The duration of an infection related event is the number of 
days the symptoms of infection persists.  
[IP_ADDRESS]  Severity of Chronic Infections 
Subjects with chronic and/or frequently recurring infections record the severity of their symptoms in their 
Memory Aid . At the Initial Evaluation period prior to randomization and treatment, a baseline of their 
symptoms is documented and incorporated into their Memory Aid . During treatment, any significant 
change in baseline such as worsening infection that affects their function or require symptomatic 
treatment (e.g. , over the counter medication) are recorded, as well as any significantly improved 
symptoms that improves their function or reduces their need for symptomatic treatment (e.g. , over the 
counter medication) are computed as used as a measure of their severity of infection.  
[IP_ADDRESS]  Use of Prophylactic Antibiotics  
At the Initial Evaluation period prior to randomization and treatment, a subject’s use of prophylactic 
antibiotics is documented and incorporated into their Memo ry Aid . Subjects record their compliance with 
these prophylactics in their Memory Aid . Changes in prescription or to a subject ’s use of the prophylactic 
are recorded . Although this information is not a direct measure of a subject ’s severity of infection, i t is 
collected to provide background information that may explain  confounding or extrinsic factors that may 
affect a subject’s rate and severity of infection.  Subjects who are prescribed prophylactic antibiotics will 
be encouraged to continue them throughout the study so as to minimize any confounding.  
[IP_ADDRESS]  Control of Warts  
Existing warts will be documented at baseline visits prior to treatment with either the study drug or the 
comparator agent via clinical photographs,  if the subject  consents. Every 4 months during the treatment 
period clinical photography will be repeated in areas with new or existing warts.  Our main endpoint will 
be the number of new visible wart s occurring during each 52-week  treatment period. We will also analyze 
the size changes of existing untreated warts and the regrowth of treated/removed warts as secondary endpoints. A two-sample Wilcoxon paired difference test will be used for analysis.  
[IP_ADDRESS]  Change of Leukocyte Blood Counts  
Leukocyte numbers  available from the CBC (ANC, etc.) will be averaged throughout each 1-year 
treatment period with either the Study Drug or Comparator Drug and statistical comparison will be performed as part of the secondary endpoints.  Lymphocyte flow cytometry results (CD19+, CD4+, CD8+, etc.) will be averaged from the 4, 8, and [ADDRESS_90710] will be used for analysis. Changes in leukocyte numbers will also be analyzed by [CONTACT_83171].
   
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 61 of 74 
 
 [IP_ADDRESS]    Quality of Life and Subject Preference Assessment 
The subject s will complete a  validated  Quality of Life (QOL) questionnaire  (SF-36 version 2) during the 
4, 8, and [ADDRESS_90711] been assigned initial treatment 
with G-CSF and 2 will ha ve been assigned initial treatment with plerixafor . 
15 ETHICS/PROTECTION OF  HUMAN SUBJECTS  
15.[ADDRESS_90712]'s involvement in the research. Discussions about the research will provide essential 
information about  the study and will include the purpose, duration,  experimental procedures, alternatives, 
and risks and benefits. Subjects will be given the opportunity to ask questions and have them answered.  
 Subjects will sign the informed consent documents prior to undergoing any research procedures. Subjects may wi thdraw consent at any time throughout the course of the study. A copy of the informed consent 
documents will be given to the subjects for their records. The researcher will document the signing of the consent forms in the subject’s medical record. The rights and welfare of the subjects will be protected by [CONTACT_83192].  
 
The acquisition of main study informed consent will be documented i n the participant’s medical records, 
as required by 21 CFR 312.62. The informed consent form will be signed and personally dated by [CONTACT_83193]. The original signed informed consent form will be retai ned in the subjects’ medical chart and a copy of it will be provided to them .  
 Consent from Non-English Speaking Participants  
If a non -English speaking participant is unexpectedly eligible for enrollment, the participant will be 
provided with the CC Short  Written Consent Form for Non-English Speaking Research Participants in the 
participant’s native language and a verbal explanation of the purpose, procedures and risks of the study as described MAS Policy M77 -2, NIH HRPP SOP 12 and 45 CFR 46.117(b)(2). The  IRB-approved English 
consent form will serve as basis for the verbal explanation of the study. The investigator will obtain an 
interpreter unless the investigator is fluent in the prospective participant’s language. Preferably, the 
interpreter will be som eone who is independent of the participant (i.e., not a family member). Interpreters 
provided by [CONTACT_79849]. The interpreters will translate the IRB -approved 
English consent form verbatim and facilitate discussion between the participant and investigator.  
The IRB-approved English consent form will be signed by [CONTACT_83194] a 
witness to the oral presentation. The CC Short Written Consent Form will be signed by [CONTACT_4538] a witness who observed th e presentation of information. The interpreter may sign the consent 
document as the witness and, in this case, will note “Interpreter” under the signature [CONTACT_4548]. A copy of both signed forms will be provided to the participant to take home.  
 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 62 of 74 
 
 The investigator  obtaining consent will document the consent process in the participant’s medical record, 
including the name [CONTACT_4549]. Further, all instances of use of the CC Short Written Consent Form will be reported to the IRB at the time of annual review. If  the CC Short Written Consent Form is used 
three times or more for the same language, this will be reported to the IRB immediately.  
15.[ADDRESS_90713] Confidentiality  
The investigator will ensure that the subjects’ anonymity is maintained. Subjects will not be identified in 
any publicly released reports of this study. All records will be kept confidential to the extent provided by 
[CONTACT_1032], state, and local law. The study monitors and other authorized representatives of the sponsor may 
inspect all documents and records required to be maintained by [CONTACT_093], including, but not limited to, medical records. The investigator will inform the subjects that the above -named representatives will 
review their study -related records without violating their confidentiality. To maintain subject 
confidentiality, all laboratory specimens, evaluation forms, reports, and other records that leave the site 
will be identified only by a coded number to maintain subjects’ confidentiality. All records will be kept locked and all computer entry and networking programs will be done with coded numbers only. Clinical information will not be released without written permission of the subject, except as necessary for monitoring by [CONTACT_1744], FDA, NIAID, O HRP , or the sponsor’s designee.  
[ADDRESS_90714] KEEPI[INVESTIGATOR_1645]  
16.1 Data Management Responsibilities  
The investigator is responsible for assuring that the data collected is complete, accurate, and recorded in a timely manner. Source documentation (the point of initial recording of information) should support the data collected in the electronic data system , and must be signed and dated by [CONTACT_1024]/or 
reviewing the data. All the data should be reviewed by [CONTACT_83195] .  
16.2 Data Capture Methods  
Study data will be collected at the study site and maintained in an electronic data system . These forms or 
systems are to be completed on an ongoing basis during the study. Only a uthorized individuals shall 
perform data ent ry into the electronic data system. Corrections to the electronic data system  shall be 
tracked electronically (password protected or through an audit trail) with the time, date, name [CONTACT_83202], and details of the change being made.  
16.[ADDRESS_90715]’s medical records, laboratory reports, EKG tracings, x -rays, radiologist’s reports, subject’s diaries, biopsy reports, ultrasound photographs, progress 
notes, pharmacy records, and any other similar reports or records of procedures performed during the subject’s participation in the study  
16.4 Source Documents and Access to Source Data/Documents  
Study data will be collected and maintained in NIH-CC electronic records, and the subject’s study binder . 
The PI [INVESTIGATOR_83130], accurate, and recorded in a timely 
manner. Source documentation (the point of initial recording of a pi[INVESTIGATOR_83131]) shoul d support the data 
collected, and must  be signed and dated by [CONTACT_1024]/or reviewing the data. Source 
documents include all recordings of observations or notations of clinical activities and all reports and records necessary for the evaluation and reconstruction of the clinical trial. Source documents include, but 
are not limited to, the subject’s medical records, laboratory reports, progress notes, pharmacy records and any other similar reports or records of procedures performed during the subject’s participation in the 
study. Data from the  data s ystem will be collected directly from the subjects during study visits or will be 
abstracted from the subjects’ medical records. Each subject’s medical record must record his/her 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 63 of 74 
 
 participation in the clinical trial and study agent (with doses) and any other medical interventions or treatments administered, as well as any adverse reactions experienced during the trial.    
 
To maintain the subjects’ confidentiality, access to the data will be limited. Authorized representatives 
from NIAID and reg ulatory agencies will be permitted to examine clinical records for the purposes of 
quality assurance review, audits, and evaluation of the study safety and progress.  
16.5 Study Records Retention  
The investigator is responsible for retaining all essential documents listed in the ICH GCP guideline. Essential documentation for all the study subjects is to be maintained by [CONTACT_83196] a secure 
storage facility for a minimum of 3 years according to NIAID policies.  The FDA requires study records to 
be retained for up to 2 years after marketing approval or disapproval (21 CFR 312.62), or until at least [ADDRESS_90716]. All stored records are to be kept confidential to the extent required by [CONTACT_1032], state, and local law.  
 Should the investigator wish to assign the study records to another party and/or move them to another 
location, the investigator must provide written notification of such intent to OCRPRO /NIAID, with the 
name [CONTACT_40756]/or their new location. Prior to the destruction or relocation of research records, NIAID must be notified in writing and written 
permission from OCRPRO /NIAID is required.  
  
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 64 of 74 
 
 17 REFERENCES  
1. Kawai, T., and Malech, H.L. 2009. WHIM syndrome: congenital immune deficiency disease. Curr Opin Hematol  16:20- 26. 
2. McDermott, D.H., Lopez, J., Deng, F., Liu, Q., Ojode, T., Chen, H., Ulrick, J., Kwatemaa, N., Kelly, C., Anaya -O'Brien, S., Garofalo, M., Marquesen, M., Hilligoss, D., DeCastro, R., Malech, 
H.L., and Murphy, P.M. 2011. AMD3100 is a potent antagonist at CXCR4(R334X) , a hyperfunctional mutant chemokine receptor and cause of WHIM syndrome. J Cell Mol Med  
15:2071-2081.  
3. McDermott, D.H., Liu, Q., Ulrick, J., Kwatemaa, N., Anaya -O'Brien, S., Penzak, S.R., Filho, 
J.O., Priel, D.A., Kelly, C., Garofalo, M., Littel, P., Marquesen, M.M., Hilligoss, D., Decastro, R., Fleisher, T.A., Kuhns, D.B., Malech, H.L., and Murphy, P.M. 2011. The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome. Blood  118:4957-4962.  
4. Dale, D.C., Bolyard, A.A., Kelley, M.L., Westrup, E.C., Makaryan, V., Aprikyan, A., Wood, B., and Hsu, F.J. 2011. The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, 
WHIM syndrome. Blood  118:4963-4966.  
5. McDermott, D.H., Liu, Q., Velez, D., Lopez, L., Anaya -O'Brien, S., Ulrick, J., Kwatemaa, N., 
Starling, J., Fleisher, T.A., Priel, D.A., et al. 2014. A phase [ADDRESS_90717] plerixafor. Blood  123:2308 -2316.  
6. Allen, S.J., Crown, S.E., and Handel, T.M. 2007. Chemokine: receptor structure, interactions, and antagonism. Annu Rev Immunol  25:787-820.  
7. Murphy, P.M. 2002. International Union of Pharmacology. XXX. Update on chemokine receptor 
nomenclature. Pharmaco l Rev  54:227-229.  
8. Zou, Y.R., Kottmann, A.H., Kuroda, M., Taniuchi, I., and Littman, D.R. 1998. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature  393:595-
599. 
9. Kawai, T., Choi, U., Cardwell, L., DeRavin, S.S., Naumann, N., Whiting -Theobald, N.L., Linton, 
G.F., Moon, J., Murphy, P.M., and Malech, H.L. 2007. WHIM syndrome myelokathexis reproduced in the NOD/SCID mouse xenotransplant model engrafted with healthy human stem cells transduced with C -terminus -trun cated CXCR4. Blood  109:78- 84. 
10. Hendrix, C.W., Collier, A.C., Lederman, M.M., Schols, D., Pollard, R.B., Brown, S., Jackson, 
J.B., Coombs, R.W., Glesby, M.J., Flexner, C.W., Bridger, G.J., Badel, K., MacFarland, R.T., 
Henson, G.W., and Calandra, G. 2004.  Safety, pharmacokinetics, and antiviral activity of 
AMD3100, a selective CXCR4 receptor inhibitor, in HIV-[ADDRESS_90718]  37:1253-1262.  
11. Kawai, T., Choi, U., Whiting -Theobald, N.L., Linton, G.F., Brenner, S., Sechler, J.M., Murphy, 
P.M., and Malech, H.L. 2005. Enhanced function with decreased internalization of carboxy -
terminus truncated CXCR4 responsible for WHIM syndrome. Exp Hematol 33:460-468.  
12. Hernandez, P.A., Gorlin, R.J., Lukens, J.N., Taniuchi, S., Bohinjec, J., Francois, F., Klotman, M.E., and Diaz, G.A. 2003. Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease. Nat Genet  34:70-74.  
13. Diaz, G.A. 2005. CXCR4 mutations in WHIM syndrome: a misguided immune system? Immunol 
Rev 203:235-243.  
14. Orsini, M.J., Parent, J.L., Mundell, S.J., Marchese, A., and Benovic, J.L. 1999. Trafficking of the HIV coreceptor CXCR4. Role of arrestins and identification of residues in the c-terminal tail that mediate receptor internalization. J Biol Chem 274:[ZIP_CODE]-[ZIP_CODE].  
15. Dotta, L., Tassone, L., and Badolato, R. 2011. Clinical and genetic features of Warts, 
Hypogammaglobulinemia, Infections and Myelokathexis (WHIM) syndrome. Curr Mol Med  
11:317-325.  
16. Gulino, A.V., Moratto, D., Sozzani, S., Cavadini, P., Otero, K., Tassone, L., Imberti, L., 
Pi[INVESTIGATOR_83132], S., Notarangelo, L.D., Soresina, R., Mazzolari, E., Nelson, D.L., and Badolato, R. 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 65 of 74 
 
 2004. Altered leukocyte response to CXCL12 in patients with warts hypogammaglobulinemia, infections, myelokathexis (WHIM) syndrome. Blood 104:444- 452. 
17. Balabanian, K., Levoye, A., Klemm, L., Lagane, B., Hermine, O., Harriague, J., Baleux, F., 
Arenzana-S eisdedos, F., and Bachelerie, F. 2008. Leukocyte analysis from WHIM syndrome 
patients reveals a pi[INVESTIGATOR_83133]3 in CXCR4 signaling. J Clin Invest  118:1074-1084.  
18. Balabanian, K., Brotin, E., Biajoux, V., Bouchet-Delbos, L., Lainey, E., Fenneteau, O., Bonnet, 
D., Fiette, L., Emilie, D., and Bachelerie, F. 2012. Proper desensitization of CXCR4 is required for lymphocyte development and peripheral compartmentalization in mice. Blood 119:5722- 5730.  
19. Murphy, P.M., and McDermott, D.H. 2012. Unexpected developments in immune organs in WHIM syndrome. Blood  119:5610-5612.  
20. Mc Guire, P.J., Cunningham -Rundles, C., Ochs, H., and Diaz, G.A. 2010. Oligoclonality, 
impaired class switch and B-cell memory responses in WHIM syndrome. Clin Immunol  135:412-
421. 
21. Chae, K.M., Ertle, J.O., and Tharp, M.D. 2001. B -cell lymphoma in a patient with WHIM 
syndrome. J Am Acad Dermatol  44:124 -128.  
22. Imashuku, S., Miyagawa, A., Chiyonobu, T., Ishida, H., Yoshihara, T., Teramura, T., Kuriyama, K., Imamura, T., Hibi, S., Morimoto, A., and Todo, S. 2002. Epstein -Barr virus-associated T -
lymphoproliferative disease with hemophagocytic syndrome, followed by [CONTACT_83197] B lymphoma in a young adult female with WHIM syndrome. Warts, hypogammaglobulinemia, 
infections, and myelo kathexis. Ann Hematol  81:470 -473.  
23. Badolato, R., Dotta, L., Tassone, L., Amendola, G., Porta, F., Locatelli, F., Notarangelo, L.D., 
Bertrand, Y., Bachelerie, F., and Donadieu, J. 2012. Tetralogy of fallot is an uncommon manifestation of warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. J 
Pediatr  161:763-765.  
24. Dale, D.C., Bonilla, M.A., Davis, M.W., Nakanishi, A.M., Hammond, W.P., Kurtzberg, J., Wang, W., Jakubowski, A., Winton, E., Lalezari, P., and et al. 1993. A randomized contro lled phase III 
trial of recombinant human granulocyte colony -stimulating factor (filgrastim) for treatment of 
severe chronic neutropenia. Blood  81:2496-2502.  
25. Beaussant Cohen, S., Fenneteau, O., Plouvier, E., Rohrlich, P.S., Daltroff, G., Plantier, I., Dupuy, A., Kerob, D., Beaupain, B., Bordigoni, P., Fouyssac, F., Delezoide, A.L., Devouassoux, G., 
Nicolas, J.F., Bensaid, P., Bertrand, Y., Balabanian, K., Chantelot, C.B., Bachelerie, F., and 
Donadieu, J. 2012. Description and outcome of a cohort of 8 pa tients with WHIM syndrome from 
the French Severe Chronic Neutropenia Registry. Orphanet J Rare Dis 7:71.  
26. Calandra, G., Bridger, G., and Fricker, S. 2010. CXCR4 in clinical hematology. Curr Top Microbiol Immunol  341:173 -191.  
27. De Clercq, E. 2009. The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil). Biochem Pharmacol  77:1655- 1664.  
28. DiPersio, J.F., Micallef, I.N., Stiff, P.J., Bolwell, B.J., Maziarz, R.T., Jacobsen, E., Nademanee, A., McCarty, J., Br idger, G., and Calandra, G. 2009. Phase III prospective randomized double -
blind placebo-controlled trial of plerixafor plus granulocyte colony -stimulating factor compared 
with placebo plus granulocyte colony -stimulating factor for autologous stem -cell mobilization 
and transplantation for patients with non -Hodgkin's lymphoma. J Clin Oncol 27:4767- 4773.  
29. DiPersio, J.F., Stadtmauer, E.A., Nademanee, A., Micallef, I.N., Stiff, P.J., Kaufman, J.L., Maziarz, R.T., Hosing, C., Fruehauf, S., Horwitz, M., Cooper, D., Bridger, G., and Calandra, G. 
2009. plerixafor  and G -CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for 
autologous stem cell transplantation in patients with multiple myeloma. Blood  113:5720-5726.  
30. Lack, N.A., Green, B., Dale, D. C., Calandra, G.B., Lee, H., MacFarland, R.T., Badel, K., Liles, 
W.C., and Bridger, G. 2005. A pharmacokinetic -pharmacodynamic model for the mobilization of 
CD34+ hematopoietic progenitor cells by [CONTACT_83198]3100. Clin Pharmacol Ther  77:427-436.  
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 66 of 74 
 
 31. Nagasawa, T., Hirota, S., Tachibana, K., Takakura, N., Nishikawa, S., Kitamura, Y., Yoshida, N., 
Kikutani, H., and Kishimoto, T. 1996. Defects of B -cell lymphopoiesis and bone -marrow 
myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature  382:635-638.  
32. Ma, Q., Jones, D., Borghesani, P.R., Segal, R.A., Nagasawa, T., Kishimoto, T., Bronson, R.T., 
and Springer, T.A. 1998. Impaired B -lymphopoiesis, myelopoiesis, and derailed cerebellar 
neuron migration in CXCR4- and SDF -1-deficient mice. Proc Natl Acad Sci U S A  95:9448- 9453.  
33. Gabrilove, J.L., Jakubowski, A., Fain, K., Grous, J., Scher, H., Sternberg, C., Yagoda, A., Clarkson, B., Bonilla, M.A., Oettgen, H.F., and et al. 1988. Phase I study of granulocyte colony -
stimulating factor in patients with transitional cell carcinoma of the urothelium. J Clin Invest  
82:1454-1461.  
34. Morstyn, G., Campbell, L., Souza, L.M., Alton, N.K., Keech, J., Green, M., Sheridan, W., Metcalf, D., and Fox, R. 1988. Effect of granulocyte colony stimulating factor on neutropenia induce d by [CONTACT_33436]. Lancet 1:667-672.  
35. Bronchud, M.H., Scarffe, J.H., Thatcher, N., Crowther, D., Souza, L.M., Alton, N.K., Testa, 
N.G., and Dexter, T.M. 1987. Phase I/II study of recombinant human granulocyte colony -
stimulating factor in patie nts receiving intensive chemotherapy for small cell lung cancer. Br J 
Cancer 56:809-813.  
36. Rosenberg, P.S., Zeidler, C., Bolyard, A.A., Alter, B.P., Bonilla, M.A., Boxer, L.A., Dror, Y., 
Kinsey, S., Link, D.C., Newburger, P.E., Shimamura, A., Welte, K., and Dale, D.C. 2010. Stable 
long-term risk of leukaemia in patients with severe congenital neutropenia maintained on G- CSF 
therapy. Br J Haematol  150:196- 199. 
37. Connelly, J.A., Choi, S.W., and Levine, J.E. 2012. Hematopoietic stem cell transplantation for 
severe congenital neutropenia. Curr Opin Hematol  19:44-51.  
38. Nagasawa, T., Nakajima, T., Tachibana, K., Iizasa, H., Bleul, C.C., Yoshie, O., Matsushima, K., 
Yoshida, N., Springer, T.A., and Kishimoto, T. 1996. Molecular cloning and characterization of a 
murine pre -B-cell growth -stimulating factor/stromal cell-derived factor 1 receptor, a murine 
homolog of the human immunodeficiency virus 1 entry coreceptor fusin. Proc Natl Acad Sci U S 
A 93:[ZIP_CODE]-[ZIP_CODE].  
39. Vettenranta, K., Mottonen, M., and Riikonen, P. 2012. The use of plerixafor in harvesting 
autologous stem cells in the pediatric setting. Pediatr Blood Cancer  59:197-198.  
40. Aabideen, K., Anoop, P., Ethell, M.E., and Potter, M.N. 2011. The feasibility of plerixafor as a second -line stem cell mobilizing agent in children. J Pediatr Hematol Oncol  33:65-67.  
 
 
 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
 
APPENDIX A: SCHED ULE OF PROCEDURES AND EVALUATION 
 
 
 
 
 
 
Evaluations  
Screening, Initial 
Evaluation Period and 
Baseline Assessments  
(Screening & Baseline)   
[ADDRESS_90719]
P Equilibration Period  
(Day Prior, Day 0, & Local Labs)   
 
[ADDRESS_90720]
P Year Treatment Period (52 
weeks)   
2 Pnd
P Equilibration 
& 2 Pnd
P Year 
Treatment Pa 
  
Reversion to  
Pre-study Treatment 
Screening 
V1 
W –(2 to 
20) Baseline 
V2 Prior  to 
Injection 
V3 
D -1/[ADDRESS_90721]
P Dose 
V3 
D 0 Local 
Labs Pa 
L 1, 2, 3  
W 2,  4, 6 
(± 7d) Evaluation 
V 4, 5, 6 
M 0, 4, 8 
(± 31d) Local 
Labs Pa 
L 4, 5, 6 
M 2, 6 , 10 
(± 31d) EOT 
V7 
M 12  
(± 
31d) 2 Pnd
P Study Drug Pb 
V 8-12 
L 7-12 
M13 to 26 
(± 31d)  
Local Labs Pa 
L 13-15 
W 2,  4 
(± 7d) 
M 28  
(± 31d) Study 
Completio
n 
V13 
M 30  
(± 61d) 
Informed consent  X           
Weight X  X   X  X X (x5)  
 X 
Vital Signs: Temp, Pulse, Blood Pressure X  X X Pc  X  X X (x6)  
 X 
Pregnancy testing  as applicable and 
contraception counseling as appropriate.  X  X   X  X X (x5)  
 X 
CBC with Differential X L X  L X L X X (x5) 
L (x6)   
L X 
ESR and Chemistry Pd X L X X L X L X X (x6)  
L X 
Vitamin B12, Folate   X       X X   
PT/PTT , Urinalysis, Viral Panel Pe
P     
X           
 
EKG   
X  
       
X  
X   
 
Echocardiogram (within 5 years)   
X           
History, Medications, Allergies, 
contraceptive counseling, and Physical 
Exam     
X   
X    
X  
  
X  
X (x4)   
X 
Review/adjust subject’s IVIg, 
prophylactic antibiotic and G- CSF dose   
X    
  
      
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 68 of 74 
 
  
Ultrasonogram of the spleen, DEXA Scan    
X       
X  
X   
Quantitative Immunoglob ulin and 
Leukocyte Phenotypi[INVESTIGATOR_007]. Research blood 
as required.    
X  
X    
X   
X  
X (x5)   
X 
Antibody levels  
(Includes Tetanus, Diphtheria)   X      X X   
Photographs of cutaneous Warts  
(Photo of genital Warts is optional)    
X     
X  
  
X  
X (x4)   
X 
Standard Consults: Dermatology, Dental, 
GYN, ENT and Audiology    
X     
   
X  
X   
 
Additional Procedures/Consults if 
clinically indicated: PFT, chest- CT, 
sinus -CT, etc.    
X     
   
X  
X   
 
QOL (SF- 36v2) Questionnaire   X    X  X X (x4)   
Training/Review: Memory Aid , local 
labs, drug shipment, storage, and 
administration     X X        
  
Randomization   X          
G-CSF or plerixafor stopped at least [ADDRESS_90722]
P day of injection    
X       
X  
X  
Optional: wart, skin, & bone marrow 
biopsies    
O     
O  
  
O  
O   
O 
Submission and review of subject 
Memory Aid   X X (x4) X (x26) X (x30)  
X (x10)  
AE monitoring   X X (x4) X (x26) X (x30)  
X (x10)  
V=visit; D=study Day; d= days; W=Study Week (from start of [ADDRESS_90723]
P injection); M= Study Month; O=Optional; L= may be performed at subject’s Local facility; G- CSF=granulocyte colony stimulating factor;  
CBC=complete blood count; ESR; PT/PTT=prothrombin time/partial thromboplastin time; EKG=electrocardiogram; ENT=ear, nose, and throat; QOL=Quality of Life; AEs=ad verse events.  
Pa
PLocal Labs: Subjects may obtain their laboratory tests locally and the results sent to the NIH. If practical, provisions will be made for labs to be drawn at a Quest facility, at no cost, and accessible to the subject. ESR 
test is optional for local lab draws.  
Pb
P Column represents the summation and aggregate of the activities for the Equilibration and Treatment Period of the second (alternate) study drug.  
Pc
PIn addition to vital signs, orthostatic pulse and blood pressure should be measured prior to injection and 60 +/ - 20m post injection.  
Pd
PChemistry: NIH -Acute Care Panel, Hepatic Panel, Mineral Panel, Serum Protein, Lactate Dehydrogenase, Serum Uric Acid, & Creatine Kinase, and ESR. For home monitoring (local labs), BUN and creatinine are 
required.  Additional chemistries labs may be requested, and ESR if available may be requested.   
Pe
PThis includes HIV, hepatitis B/C.  HTLV type [ADDRESS_90724] body temperature, fever, symptoms of infection, and anti- infective treatments/prophylaxis on a daily basis, and how to self -administer the study drugs.
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
 
APPENDIX B: FDA APPROVED PACKAGED INSERT: PLERIXAFOR  
 
Plerix afor (Mozobil ™) is an FDA approved product .  The approved package insert is considered a 
comprehensive source of safety data. The current version of the package insert is available on the 
Mozobil ™ website ( http://products.sanofi.us/Mozobil/mozobil.html).  
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
 
APPENDIX C: FDA APPROVED PACKAGE INSERT: G- CSF  
 
G-CSF , Neupogen PTM 
P(filgrastim)  is an FDA-approved drug. T he approved package insert  is considered a 
comprehensive source of safety data. The current version of the package insert is available on the 
Neupogen PTM
P website ( 40Thttp://pi.amgen.com/united_states/neupogen/neupogen_pi_hcp_english.pdf 40T). 
 
  
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 71 of 74 
 
 APPENDIX D: INFECTION SEVERITY SCORE (IS S) 
 
Type of Infection  Fever  Anti-Infective  Hospi[INVESTIGATOR_83134]  
  0:  No chills/fever  0:  No Treatment  0:  No Hospi[INVESTIGATOR_059]   
1:  Non-sterile site  1:  38.3 -39º C 1:  Topi[INVESTIGATOR_2855]  1:  Emergency Room   
2:  Sterile site  2:  > 39 º C 2:  Oral  2:  Hospi[INVESTIGATOR_9651]  
    3:  Parenteral  3:  ICU   
     
[ADDRESS_90725], and skin; while, sterile sites 
would include th e lower respi[INVESTIGATOR_4352], blood, muscle, bone, joints, urinary bladder, and other typi[INVESTIGATOR_83135].  Fever will refer to the maximum oral temperature recorded during the infection.  Anti-
infective treatment is scored based on the highest level of treatment i.e. intravenous antibiotic that is 
changed to oral would score a 3.  Similarly hospi[INVESTIGATOR_83136].  Scores for each parameter will be added and thus the score for any given incidence of infection can range from 1-10.   
    
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
_____________________________________________________________________________________________ 
  
Page 72 of 74 
 
 APPENDIX E: DOSING OF PLEXIFOR IN RENAL IMPAIRMENT  
 In subject s with moderate and severe renal impairment (estimated creatinine clearance [CrCl] ≤50 
mL/min), each dose of plerixafor ( Mozobil
PTM
P ) will be reduced b y one -third. Because of the renal 
excretion of the drug, this reduction in subjects with moderate and severe renal impairment is expected to 
result in similar drug levels compared with subjects with normal renal function.  
  
The following (Cockroft-Gault) formula may be used to estimate Creatinine Clearance (CrCl):   
 
Males:  
    Cr eatinine clearance (mL/min) = 17Tweight (kg) X (140 – age in years) 17T 
                                                        72 X serum creatinine (mg/dL)  
     
Females:  
    Creatinine clearance (mL/min) = 0.[ADDRESS_90726] a CrCl <15 ml/min are excluded from this study.  
 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
 
APPENDIX F: SAMPLE SUBJECT MEMORY AID  
Study Contact [CONTACT_7171]: Email and Phone # 
Date  
MM/DD/YY    Complete each question by [CONTACT_83199].  
Infection Related Treatments         
Drug 1  Route  Frequency  Yes   No    
Drug 2  Route  Frequency  Yes   No   
Additional Antibiotics:  Route:  Frequency:  No   Yes   
Study Drug and Side Effects        
Morning Injection  Batch ID   Site of Injection    No     
Evening Injection  Batch ID  Site of Injection    No     
Morning Injection Site Reaction  None    Tenderness  Pain  Ulceration  
Evening Injection Site Reaction  None    Tenderness  Pain  Ulceration  
Bone/Skeletal Pain (arms, legs, back)  None    Mild  Affects Function  Affects Self -care  
Pain (abdomen, shoulder etc.)  None    Mild  Affects Function  Affects Self -care  
Headache  None    Mild  Affects Function  Affects Self -care  
Dizziness  None    Unsteadiness  Affects Function  Affects Self -care  
Nausea  None    Loss of Appetite  Reduced Oral Intake  Tube Feeding  
Vomiting  None    [ADDRESS_90727]:  No   Mild  Affects Function  Affects Self -care  
Additional Side Effect:  No   Mild  Affects Function  Affects Self -care  
Fevers and Infections  (please inform study staff)        
Record your highest temp for the day  Enter Temp      
Missed School/Work due to side effect of s tudy drug  No   Partial Day  Full Day    
Missed School/Work because of Infection  No   Partial Day  Full Day    
Visits to the [CONTACT_83203] to Doctor for Infection or Side Effects  No   Visit  to [CONTACT_83204][INVESTIGATOR_83137]:  Route:  Frequency:  Taken    Not Taken    
Treatment:  Route:  Frequency:  Taken    Not Taken    
Please inform study staff of any events that are disabling or require immediate medical attention.  
Notes:         
          
        
        
        
Legend:         
Bolded Entries  Prefilled by [CONTACT_83200] [ADDRESS_90728]      
Plerixafor  vs. G -CSF in WHIMS – Version 6.0 
January 9, 2019 
 
 
APPENDIX G: EVALUATION OF INFECTION FORM  
 
Directions: Please circle relevant items and fill in underlined sections.  Use a different form for each 
infection unless contiguous and related.   
 
1) Date of Office or ER Visit, Hospi[INVESTIGATOR_059]:_________________________  
 
2) Chief Complaint:_____________________________________________________  
 3) Date of Onset of Symptoms:_________________________________________  
 4) Diagnosis  (New / Chronic / Recurrent / Exacerbation) :  Otitis, Sinusitis, Dental Infection, Pharyngitis, 
Other oral infection, Bronchitis, Pneumonia, Cellulitis, Cutaneous abscess, Osteomyelitis, Endocarditis, Meningitis, Joint Infection, Gastroenteritis, urinary tract infection, unknown  
Other or further information:  ______________________________________  
 5) Site of Infection:____________________________________  
 6) Likely Cause of Infection: Viral, Bacterial, Fungal, Parasite, Unknown,  
 Other: ________________________________________       
 
7) Treatment Prescribed: __________________________________________________________  
 
8) Route of Treatment: Topi[INVESTIGATOR_2855], Oral, intravenous  
 9) Length of Treatment Prescribed (days):_______________________________________  
 Relevant Laboratory Results:  10) Culture/Test Result: _____________________________________ pending or not performed.  
 11) Outcome of  Infection:  Pending, Unknown, Resolved, Resolved with residual symptoms, Ongoing,  
 Other:_____________________________  
 12) Additional Information (optional): ____________________________________________  
 